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Chapter 1: General Introduction 
Introduction 
Ras proteins are members of the family of monomelic small guanine nucleotide 
binding proteins. Ras proteins play key roles in many signal transduction pathways. By the 
different anchor motifs at the carboxyl terminus, Ras proteins can bind to the inner leaflet of 
the plasma membrane and signal from there. When signaling, Ras proteins switch between 
the active or non-active state depending upon the status of their GTP or GDP binding. 
Activating mutations of Ras proteins are found in -30% of all human tumors [1] and this 
makes Ras proteins a very important target for cancer therapy. 
In mammalian cells, four isoforms of Ras protein: H-Ras, N-Ras, K-Ras 4A and K-
Ras 4B are found [2]. Although they are highly homologous, H-Ras, N-Ras and K-Ras are 
not functionally identical [3-7]. All the Ras proteins end with a specific sequence, termed a 
CAAX motif, which is a motif for a series of posttranslational modifications of the C-
terminus that are found on many isoprenylated proteins [8]. After these modifications, H-Ras, 
N-Ras and K-Ras 4A undergo another round of lipid modification, which is palmitoylation 
of cysteine residues adjacent to the famesylated one [8], These lipid modifications make Ras 
proteins anchor on the membranes. K-Ras 4B does not go through the palmaitoylation step, 
since it does not have the potential palmitoylation site. Instead, it uses a polybasic region, 
which is comprised of six contiguous lysine residues, as the anchor for the membrane 
targeting. The difference of the mechanisms for the membrane anchoring makes the Ras 
proteins use different pathways for their transport to the plasma membrane. 
After accepting their posttranslational modifications, H-Ras, N-Ras and probably K-
Ras 4A can be transported to the plasma membrane through the classical vesicular exocytic 
pathway [9-14]. However, whether this is the only pathway is still under investigation. K-
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Ras 4B on the other hand, may just use simple diffusion to get to the plasma membrane [15-
19]. 
The plasma membrane is the major destination of Ras proteins, and is also the most 
important platform for signal transduction of them. The major Ras signal transduction 
pathways, including Raf/MEK/ERK and PI3Kinase/Akt, happen on the plasma membrane. 
Targeting to the plasma membrane is indispensable for Ras proteins to function biologically 
[20-25]. However, during recent years, new evidence has suggested that the plasma 
membrane may not be the only platform for Ras proteins localization and signal transduction 
[26-30], These discoveries open a new page on understanding Ras protein signaling. 
Difference between the non-plasma membrane- and the plasma membrane-based signaling is 
a new interesting area that needs to be explored. 
Once Ras proteins are localized on the plasma membrane, the association with the 
membrane is not constant but dynamic. There are three types of dynamic membrane 
interactions. One newly discovered type involves de-palmitoylation/re-palmitoylation that 
induces dissociation/re-association with plasma membrane[13, 31, 32]. Another involves 
vesicular endocytosis/exocytosis [33] and a third involves movement within the plane of the 
plasma membrane by partitioning into or leaving the lipid raft microdomain upon 
inactivation/activation [34-38]. 
As mentioned previously, H-Ras proteins can use a conventional pathway for traffic 
to the plasma membrane. Whether this is the only pathway taken is still unknown. In this 
study we investigated the transportation pathway of H-Ras and discovered a novel pathway 
for it's trafficking. This is a non-conventional pathway and to date, very few studies have 
been undertaken to investigate such pathways. With this work we not only revealed a new 
mechanism for H-Ras traffic, but also may uncover a new posttranslational modification 
procedure for H-Ras, since in this pathway H-Ras might not be palmitoylated at Golgi But 
the plasma membrane instead. We also studied H-Ras signal transduction from 
3 
endomembranes, which revealed subtle but distinct differences of H-Ras signaling on 
different membranes. Finally we improved the biochemical method for isolation of lipid 
rafts and using this new tool we demonstrated H-Ras protein is essentially localized in the 
non-lipid raft microdomains, regardless of its nucleotide state. 
Thesis Organization 
This dissertation is comprised of a general introduction about Ras proteins and two 
manuscripts about H-Ras trafficking and signal transduction. An independent chapter in 
manuscript format follows, which is about membrane micro-localization of H-Ras. The last 
chapter is the summary of the whole work. The general introduction part will include a 
literature review, which describes the current opinions about Ras proteins, posttranslational 
modification of Ras proteins, lipid Raft and membrane microdomains, and vesicular 
transport between ER and Golgi. The next two chapters are manuscripts in preparation for 
submission to the Journal of Cell Biology and Journal of Biological Chemistry. The first 
paper, "H-Ras does not need Sari-dependent vesicular transport or a functional Golgi to 
reach the plasma membrane" describes a novel traffic pathway H-Ras uses for plasma 
membrane targeting. The second manuscript " Two new C-terminal variants of H-Ras that 
are trapped on endomembranes show similar effector interactions but distinct biological 
activities" presents the results of a study on H-Ras signaling from endomembranes. The third 
chapter "Determination of the micro-location of H-Ras on the plasma membrane" has been 
published in the Journal of Biological Chemistry. I am the major contributor to chapters 2 
and 3. A major portion of the work in the JBC paper was carried out by Tara Baker, who is 
the first author. My contributions were also substantial, and are described in a statement 
which details my specific contributions to this paper. The last chapter is a general discussion 
of the results and conclusions drawn from them. 
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Literature Review 
General Ras Proteins 
The Ras(rat sarcoma) protein was first found in 1964 [39] from the Harvey strain of 
transforming retrovirus. Shortly after (1969), another isoform of a Ras protein was also 
found in the Kirsten strain of virus [40]. Subsequently, human versions of Ras proteins were 
isolated from tumor cells [41-43], Activated forms of K-Ras mutants were found in many 
types of human cancer cells, e.g. non-small cell lung cancer (15-20% of tumors), colon 
adenomas (40%), and pancreatic adenocarcinomas (95%) [44]. More than half of the most 
malignant thyroid tumors have mutations in H-Ras, K-Ras or N-Ras [45]. All together about 
30% of human cancers contain mutations in Ras genes [1], 
The human genome encodes four isoforms of Ras protein: H-Ras, N-Ras, K-Ras 4A 
and K-Ras 4B. The two isoforms of K-Ras are the result of alternative RNA splicing of the 
fourth exon [2], All of the four isoforms of Ras proteins are highly conserved in the amino 
acid residues. The first 86 N-terminal residues are 100% identical among the four Ras 
proteins. In this region the Ras effector binding domain is included (residues 32-40). From 
86 to 185 there is an 85% homology between any pair of Ras proteins and only the last C-
terminal 23-24 residues in the mature protein, the so called hypervariable region, show 
significant differences among the isoforms [1, 2]. In the nascent protein, there are four C-
terminal residues that form a conserved CAAX box (C, cysteine; A aliphatic residue; X, 
methionine or serine), which is the motif that directs posttranslational processing for many 
isoprenylated proteins [46], 
Posttranslational Modification of Ras Proteins 
After translation, the nascent Ras peptides are famesylated at the cysteine residue of 
CAAX motif in the cytoplasm by a famesyl transferase [47]. The famesylated Ras proteins 
then bind to the cytosolic surface of the ER. On the ER a famesyl-dependent protease named 
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RCEl(Ras Converting Enzyme 1) cleaves the -AAX and leaves the carboxyl group of 
cysteine exposed for further modification. Next, the isoprenylated cysteine residue is 
methylated by a methyl transferase called Icmt (isoprenyl cysteine carboxylmethyltransferase) 
[48, 49]. These serial posttranslational modifications happen to all the Ras protein subfamily 
members (35 members), except when X=Leucine or Phenylalanine. These residues occur on 
R-Ras and some Rap proteins. For these proteins, the 20-carbon geranylgeranyl isoprenoid is 
attached, instead of farnesyl[50]. The subsequent modification is palmitoylation of H-Ras, 
N-Ras and K-Ras 4A by protein acyltransferases. This reaction may occur on the ER or 
Golgi complex[51]. Then H-Ras and N-Ras, and maybe also K-Ras 4A, are transported to 
the plasma membrane via the conventional vesicular pathway [10, 11]. A lot of studies have 
shown that palmitoylation is the modification which permits H- and N-Ras anchoring on the 
membranes and targeting to the plasma membrane [10, 12-14, 52]. K-Ras4B, which lacks 
the potential palmitoylation site, uses a polybasic domain (-KKKKKKSKTK) for membrane 
docking and targeting. This different characteristic makes K-Ras 4B behave distinctly from 
H- or N-Ras during trafficking to the plasma membrane [10, 11]. Moreover, K-Ras 4B can 
also bind to microtubules in vitro [11, 53], another unique character of this special species of 
Ras. Although there is still no direct evidence, a lot of studies suggest that the mechanism 
for K-Ras 4B transport is just simple diffusion from ER to the plasma membrane. Classically, 
the plasma membrane is thought to be the only destination for the Ras protein [54]. However 
this idea is challenged by recent studies[30]. 
Signal Transduction of Ras Proteins 
As small GTPases, all the Ras proteins use the same mechanism to regulate signal 
transduction. Upon GTP binding, a structural change happens on the two loop regions 
named switch 1 and switch 2 [55]. This change brings the Ras protein a very high affinity for 
its downstream effectors [56, 57]. This conformational change is transient and is reversed 
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when the GTP is hydrolysed and releases the y-phosphate. This reaction is facilitated by 
GTPase activating proteins (GAP). Even with the high ratio of GTP/GDP in the cell (-10 
fold [58]), the slow exchange velocity of GTP and GDP [59] makes the Ras proteins favor 
the inactive conformation in the steady state. The guanine nucleotide exchange factors 
(GEFs) can catalyze the release of GDP and therefore activate the Ras proteins. Different 
GEFs usually have some specificity for particular Ras species and thus make the regulation 
of Ras signal transduction more precise and more complicated [60] (Fig.2). 
The classic signaling site for Ras protein is the plasma membrane [61], and in many 
models it is the only site discussed for Ras signaling. This view is largely based on 
observations that mutations which cause Ras proteins to mis-localize to other places seem to 
cause loss of Ras function [62]. Nevertheless, recent studies from the group of M.R. Philips 
show some Ras proteins can signal from the ER or Golgi complex[27-29, 63], though this 
idea is again challenged by another study[25]. The signal transduction of the Ras protein at 
the Golgi complex is initiated by the classical plasma membrane signaling upon the binding 
of growth factor. However compared to the rapid and transient signaling at the plasma 
membrane, the Golgi complex signaling is delayed and sustained [27, 28, 64]. N-Ras 
signaling in T cells seems to happen on the Golgi complex only [28, 29]. The dispute of H-
Ras and N-Ras signaling on the endomembranes is mainly focused on whether these results 
are caused by the overexpression of H-Ras and N-Ras [25]. Overexpressed GTPase may 
potentially affect endogenous Ras behavior [2, 65]and there is evidence that suggests that 
endogenous GTP bound Ras is mainly activated on the plasma membrane [25]. Another 
very recent result, also from the group of M.R. Philips shows K-Ras 4B, already localized on 
the plasma membrane, can be re-directed to mitochondrial membranes upon phosphorylation 
by PKC [30]. From the mitochondrial membrane, K-Ras is proposed to induce cell apoptosis. 
Although apoptosis is a recognized function of K-Ras activity, it is much less studied than 
the more well-known functions of cell proliferation and cell differentiation. All these 
7 
studies open a new area for Ras signal transduction, based on a new model in which specific 
effector interactions arise from separate locations within the cell. This model aims to better 
understand how one protein can activate several signal transduction pathways that can cause 
different biological outcomes. 
Lipid Raft (Microdomain) and Micro-localization of Ras 
Since the first establishment of the fluid-mosaic model of the membrane [66], many 
new hypotheses were proposed to more accurately describe the structure of biological 
membranes. The lipid raft model is one of these ideas, that has been developed in the recent 
one and half decades [67-70], The central idea of this hypothesis is that the physical 
properties of cholesterol and sphingolipids may allow these lipids to form a dynamic 
microdomain within a lipid bilayer. Since the major side chains of the sphingolipids are long 
straight saturated lipids, these straight lipids make it easy for sphingolipids to form a tight 
interaction among each other and cholesterols and thus form a liquid-ordered state 
microdomain. Surrounding this microdomain (lipid raft) are the sea of phospholipids, which 
have more unsaturated kinked side chains which prevents them from tightly packing and 
makes this domain more fluid [71]. This structural feature also makes the lipid raft more 
detergent resistant than the other (liquid-disordered) part of the membrane. This has given 
these domains a second name, detergent resistant membrane (DRM), which is often found in 
the early literature. Because of the small calculated size of these domains (-50 nm diameter 
[72]), they cannot be visualized by light microscopy. This has made it very difficult to prove 
the existence of the lipid raft in live cells, and as a result, the concept of lipid raft is still a 
controversial issue [73]. 
The most important character of the lipid raft is that it can harbor discrete sets of 
proteins that differ from those found in the bulk membrane. The 
glycosylphosphatidyllinositol(GPI)-anchored proteins[74, 75], palmitoylated proteins such 
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as Hedgehog[76], double acylated proteins like Src-family kinases [73], a-subunit of the 
heterotrimeric G-protein[77] and some transmembrane proteins [78] are known to have high 
affinity for the lipid raft. This specialized protein recruitment feature gives lipid rafts an 
important role in the signal transduction. One of the first examples of signal transduction 
involving lipid rafts is in immunoglobulin E signaling [79]. Additional studies have shown 
lipid domains play important roles in T-cell antigen receptor signaling[80], B-cell receptor 
signaling[81], insulin receptor signaling [82], eNOS and Hedgehog signaling[83] etc. 
H-Ras is palmitoylated and therefore likely partitions into the lipid raft domain. 
However, there are several other properties that make this model too simplistic. The farnesyl 
group at the C-terminal end of the Ras protein is not accommodated well in an ordered 
domain and provides a repulsive force for Ras partitioning into the lipid raft. Moreover the 
linker part (166-180) in the adjacent, C-terminal hypervariable region provides an additional 
attraction to cholesterol-independent (non-raft) membrane domain[35]. Finally, the GTP 
bound state is also suggested to make H-Ras protein more likely to partition into the 
cholesterol-independent domains. A lot of work was done by the JF. Hancock group mainly 
using electron microscope (EM) imaging combined with statistical studies. In their studies, 
the lateral distribution of GTP-loaded or GDP-loaded H-Ras protein on the plasma 
membrane with or without cholesterol depletion can be obtained by EM imaging. By the 
statistical analysis of the these H-Ras distribution patterns, Hancock and his colleagues 
found GDP bound H-Ras proteins are preferably partitioned into a cholesterol-dependent 
microdomain or nanocluster, with radius about 10-22 nm. Upon the GTP binding, H-Ras 
proteins cluster into a cholesterol-independent microdomain or nanocluster. Thus, H-Ras 
may shift between lipid raft or non-raft microdomains upon the GDP or GTP binding 
respectively[35, 37, 84, 85]. 
K-Ras 4B uses a polybasic domain as its major membrane anchor motif [8, 12, 52, 
86, 87], and thus differs in its micro membrane domain partitioning. Farnesylation is critical 
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for K-Ras4B to be recruited to the membrane, and also seems to be important for it to 
associate in cholesterol-independent nanoclusters within the plasma membrane [37]. Either 
GDP loaded or GTP loaded forms of K-Ras 4B seem to localize in cholesterol-independent 
membrane domains[37, 88]. This is also distinct from the H-Ras cluster. The strong positive 
charge domain in K-Ras 4B suggests that the K-Ras 4B membrane binding site may contain 
acidic lipids. These acidic lipids might be the biophysical mechanism for the H-Ras and K-
Ras segregation[37], and also may be one possible reason why K-Ras 4B re-localizes to the 
mitochondrial membrane upon the PKC phosphorylation on the S181(which is in the 
polybasic domain), since the phosphorylation will provide more negative charge[12, 86, 87]. 
Little study has been done on the N-Ras and K-Ras4A microlocation on the plasma 
membrane. A recent report from the Hancock group shows that N-Ras exhibits an opposite 
microlocation from H-Ras upon GDP/GTP binding. That is, upon GTP binding, N-Ras 
moves into the cholesterol-dependent (raft) microdomains while it goes to the cholesterol-
independent microdomains when GDP is loaded[89]. 
Vesicular Traffic between ER and Golgi 
Movement from ER to Golgi is the first step for the classical vesicular transport path. 
H-Ras is believed to use this pathway for its targeting to the plasma membrane [10]. COP 
(coat protein complex)-coated vesicles are involved in vesicular traffic between ER and 
Golgi. There are two classes of COP vesicles. Vesicles containing COPI coat components 
traffic primarily from the Golgi back to the ER and between Golgi cistemae, while COPII-
coated vesicles traffic from the ER to the Golgi. The components of the Golgi are very 
dynamic, and the biogenesis and maintenance of Golgi is totally dependent on ER cargo 
export [90-93]. Because vesicles continuously exit the Golgi and return to the ER [90, 94, 
95], Golgi residential proteins (i.e. Giantin, manosidase, galactosyltransferase, etc.) do not 
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stably associate with the Golgi, but are cycled back to the ER and then returned to the Golgi. 
Hence, when ER export is inhibited, the Golgi structure will disappear. 
A small GTPase, Sari, is an important member of the machinery for ER export[91, 
93]. During its GTP binding and release cycle, Sari will recruit effector proteins such as 
COPH coat proteins to the ER membrane, and hence establishes ER export sites [90, 96-99]. 
A complete Sari GTP to GDP recycle is required for ER vesicular export. Thus expression 
of either the dominant negative form of Sari (T39N) or the constitutively active form of 
Sari (H79G) will block ER export. Since the retrograde traffic from Golgi to ER and other 
membranes is still going on, the net result is the disappearance of the Golgi structure. Sari 
(T39N) thus induces disassembly of the Golgi[96]. The recruitment and enrichment of 
numbers of effector proteins to the ER exporting sub-domains by Sari GTPase activity is 
just the first step for ER exporting. Further steps need activities of another small GTPase, 
Arfl. Arfl will recruit more proteins to assemble the machinery for ER membranes 
differentiating and budding. These proteins include COPI coat proteins, lipid-modifying 
enzymes and some scaffold proteins [100, 101]. The activities of these proteins and Arfl 
activity will make Golgi enzymes and cargo proteins to be more enriched in ER export sites 
and facilitate the fusion, elongation and detachment of membranes. Moreover, these proteins 
will also help recycling some enzymes in the retrograde transport back to the ER. Some 
drugs, such as Brefeldin A (BFA), can specifically block the interaction between Arfl and its 
GEF protein GBF1 and thus freeze Arfl at a GDP bound state. [102]. So by inhibiting Arfl 
activity, BFA will also block the assembly of the machinery for ER export and thus block 
the membranes budding from ER export. Since this is an indispensable part for Golgi 
genesis and maintenance, BFA treatment will also make the Golgi structure disappear. 
Current models suggest that vesicles do not go from the ER directly to the Golgi. 
Instead, they will first detach from the ER as globular-tubular elements and form a bigger 
structure that is called the ER-Golgi intermediate compartment (ERGIC). The model 
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proposes that a new cis Golgi apparatus forms by clustering and fusion of these elements[96]. 
Whether the ERGIC is formed by fusion of vesicles budding out from COPII-coated ER exit 
sites or by direct maturation of an ER exit site is still unknown[103]. 
From electron microscopy studies, the COPII-coated budding site represents only a 
small part of an ER export domain[104]. The COPII-coated export sites are not the only 
places for protein export to the secretory pathway[103, 105, 106]. There is evidence showing 
that cargos can also be exported by a tubule outgrowth through a non-coated ER export 
region[103]. 
The Golgi apparatus is a dynamic, but steady state structure, that is assembled from 
the vesicles budding from the ER and dissembled by the outgoing vesicles targeting to other 
membranes, including back to the ER. The conventional vesicular transport pathway is 
regulated by the machinery that controls the ER export site. How this traffic pathway is 
involved in movement of the Ras protein, and whether it is the only pathway used by Ras, is 
still an open issue. 
In one of my studies, we carefully compared the classical vesicular transportation 
with H-Ras transportation to the plasma membrane and found there are a lot of differences 
between these two. Our results suggest that there is a non-classical pathway for H-Ras 
transportation and that this pathway is non-vesicular, or at least not microtubules dependent. 
In a recent report, some others also showed Ras protein traffic to the plasma membrane via a 
non-classical pathway in yeast cell using a non-classical pathway [107]. Nevertheless, this 
pathway is very poorly characterized. A very recent report on potassium channel interacting 
proteins (KChlPs) [108] may shine light on this issue. In this report, the authors found 
KChlPs can help the Kv4 channels, are rapidly inactivating voltage-gated K+ channels, to 
localize on the plasma membrane, which by themselves are retained on ER and Golgi 
membranes. This KChlPs facilitated pathway is a non-COPII coated vesicular pathway. H-
12 
Ras proteins may also need proteins like KChlPs to help them get out to the plasma 
membrane when using the non-classical pathway. 
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Abstract 
New steps in the trafficking of H-Ras proteins have recently been discovered. Several 
studies now report internalization and cycling of H-Ras between intracellular membranes 
and the cell surface. Notably, both vesicular and non-vesicular mechanisms of 
internalization were described. In addition, recent biophysical studies have suggested that H-
Ras may not use a vesicular mechanism for its initial trafficking step out from the ER. Using 
immunofluorescence approaches and genetic and pharmacological inhibitors we have 
examined whether traditional vesicular transport is a requirement for any of the steps in the 
movement of H-Ras to the plasma membrane. In NIH 3T3 cells, H-Ras appears at the 
plasma membrane more rapidly than a protein carried by the traditional exocytic pathway 
and is absent largely from ER exit sites marked with Seel3. H-Ras trafficking continues 
even when COP II-directed transport from ER exit sites is disrupted by mutant forms of Sari, 
when COP I-mediated vesicular traffic from the ER to Golgi is inhibited with brefeldin A, or 
when microtubules are disrupted by nocodazole. In unperturbed cells, two-thirds show no 
evidence of H-Ras in the Golgi. Furthermore, expression of dominant negative Sari in PC 12 
cells does not prevent activated H-Ras61L from triggering neurite outgrowths. These results 
suggest that H-Ras may leave the ER directly and use a non-vesicular or microtubule-
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independent pathway to get to the plasma membrane. This unusual (dual) mechanism of 
trafficking indicates that although H-Ras can access the traditional exocytic pathway, it does 
not need conventional vesicular mechanisms for movement from the ER, and can reach and 
operate at the cell surface in the absence of a functional Golgi apparatus. 
Introduction 
Only the broad outlines of the biosynthetic transport of Ras proteins to the plasma 
membrane are known[l-3]. Mammalian H-Ras, N-Ras, and K-Ras and also yeast Ras 
proteins are initially cytosolic when they are modified on the cysteine residue of a ex­
terminai "CaaX" motif with a farnesyl isoprenoid by the farnesyl transferase. Ras proteins 
are then escorted, perhaps by the farnesyl transferase itself [4, 5], to the cytosolic face of the 
widely dispersed membranes of the endoplasmic reticulum. There an ER-resident prenyl-
dependent protease Reel removes the last three ("-aaX") residues and a second ER-resident 
enzyme (Icmt) attaches a methyl group to the newly exposed carboxyl of the farnesyl-
cysteine residue [1,3, 6-9] At this point the K-Ras4B protein is released from the surface of 
the ER and rapidly appears at the plasma membrane [10-14], No internal membrane or 
vesicular intermediates have been observed for this step, and the transport mechanism is 
currently unknown [15]. In neural cells, a very recent study reports that calcium signals 
cause calmodulin to bind to plasma membrane-bound K-Ras4B and trigger its 
internalization through a protein-mediated, cytoplasmic shuttle mechanism[16]. Thus K-
Ras4B, at least in neurons, appears to use non-vesicular means for both initial outward and 
signal-dependent, inward trafficking. 
For H-Ras, N-Ras and yeast Ras2, a second lipid modification can occur, in which 
a palmitoyl lipid is attached on additional cysteines near the farnesylated C-terminus. A two-
subunit protein acyl transferase enzyme that attaches palmitates to H-Ras and N-Ras in 
mammalian cells has only recently been identified, and may be located on Golgi membranes 
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[17-19]. In yeast, a similar two-subunit enzyme (Erf2/Erf4) that modifies yeast Ras2 has 
been found on ER membranes [18]. Another mammalian acyl transferase, Huntington 
interacting protein-14 (HIP-14), is distributed on ER/Golgi membranesand has been reported 
to enhance vesicular trafficking of multiple acylated proteins [20, 21]. Additional palmitoyl 
transferase enzymes are likely to be in the plasma membrane, because mutant yeast and 
mammalian Ras proteins that reach the plasma membrane without associating with ER or 
Golgi membranes can be palmitoylated [22], [23]. 
The release of H-Ras from the cytosolic surface of the vast ER membrane network 
is the first step in its journey to the plasma membrane. Two recent reports have laid the 
framework of this path. These studies propose the model that non-palmitoylated (but 
farnesylated) H-Ras distributes rapidly between cytosolic and transient, non-specific 
membrane-bound phases. Wherever H-Ras encounters an acyl transferase and is 
palmitoylated it becomes "kinetically trapped" on the membranes [24], and as a result, can 
then be retained on vesicles and moved onward via traditional vesicular means. The proteins 
which control vesicular trafficking at that particular point thus become relevant for H-Ras 
transport, while proteins engaged in transport at ports prior to that location are, perhaps, 
irrelevant. Furthermore, the model currently does not address whether a farnesylated H-Ras 
will need a partner protein to mask its lipid group during its cytosolic phase. These 
possibilities give importance to understanding the steps that H-Ras takes as it makes its way 
from the ER to the plasma membrane. 
A great deal is known about vesicular trafficking from the ER to the Golgi [25, 
26]. Formation of vesicles on the ER begins with assembly of a COPII complex of proteins 
around the site, termed an ER exit site (ERES), at which the newly cargo-loaded vesicle will 
form [27, 28, 29]. The protein that initiates this event is the GTPase, Sari. GTP-binding 
mutants of Sari disrupt this cycle, and inhibit COP II-mediated vesicle transport from ER to 
Golgi. In mammalian cells, the COP II vesicles that are released from the ERES then seem 
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to merge into a vesiculo-tubular center sometimes termed the ER-Golgi-intermediate 
compartment (ERGIC). From here, some vesicles move onward to the Golgi, while others 
return to the ER [30]. 
COP I-coated vesicles mediate anterograde transport from the ERGIC to Golgi, and 
retrograde traffic from Golgi membranes to the ER. The fungal product brefeldin A (BFA) 
prevents the COP I complex from binding to membranes. This causes collapse of the Golgi 
stacks, as the membranes and proteins of the Golgi rapidly drain backwards into the ER, and 
also impairs anterograde trafficking beyond the ERGIC [31] Thus, BFA inhibits vesicular 
transport at a separate point and by a mechanism distinct from that of Sari mutants. 
BFA has been reported to partially inhibit transport of a chimeric GFP protein with 
a lipidated C-terminus derived from H-Ras [3], However, another study reported continued 
transport of both H-Ras and another GTPase, TC10, to the plasma membrane in BFA-treated 
cells [32]. Thus, it is unresolved to what extent BFA-sensitive trafficking contributes to H-
Ras transport. A novel COP II-independent vesicular mechanism has recently been reported 
to transport a potassium channel subunit, KChlPl, to the plasma membrane [33]. The yeast 
Ras2 protein (which is modified by both farnesyl isoprenoid and palmitoyl lipids) also seems 
to use a non-conventional pathway for trafficking. 
Yeast Ras2 continues to reach the plasma membrane despite inhibition of vesicular 
trafficking by sec mutants that block steps both early and late in the secretory pathway [23]. 
Interestingly, yeast Ras2 uses this non-traditional pathway as long as the palmitoyl 
transferase subunits, Erf2p and Erf4p are present, but can use the conventional secretory 
pathway if Erf4p is absent. However, transport in the secondary, conventional pathway is 
less efficient, and in the absence of Erf4, produces an accumulation of Ras2 on internal 
membranes [23]. 
These precedents prompted us to examine the mechanisms by which mammalian 
H-Ras accesses the plasma membrane, with particular attention to the initial steps at its 
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release from the ER. The results indicate that two distinct routes for H-Ras transport operate 
simultaneously, and that a non-conventional, COP I- and COP II-independent mechanism 
moves the bulk of H-Ras to the plasma membrane. Unexpectedly, when the traditional route 
is blocked, H-Ras that has entered that pathway appears unable to switch to the non-
conventional pathway. This suggests that the choice of pathway, and mechanism of 
transport, is determined prior to ER disengagement. 
Materials and Methods 
Mutants, Plasmids and Antibodies H-Ras wild type, H-RasQ61L, and GFP-H-Ras 
tail were expressed from pcDNA3 (Invitrogen). YFP-GT46, YFP-SEC13 were gifts from 
Anne Kenworthy (Vanderbilt). YFP-Secl3, HA-Sarl T17N and HA-Sarl H79G were gifts 
from Dr. Jennifer Lippincott-Schwartz. Ras monoclonal antibody 238 (Santa Cruz), was 
used for immuno-fluorescence. 
Cell Culture and transaction NIH 3T3 cells and COS7 cells were cultured at 10% 
CO2 in Dulbecco's Modified Eagle's Medium (GIBCO-BRL) supplemented with 10% calf 
serum (Hyclone Laboratories). PC12 cells were maintained at 5% CO2 in RPMT 1640 
medium supplemented with 10% heat-inactivated horse serum and 5% fetal calf serum (both 
from Hyclone Laboratories). Twenty-four hours before DNA transaction, NIH 3T3 cells and 
COS7 cells were plated on the pre-washed glass cover slips (Coming) in 12 well tissue 
culture plates at a density about 105-106 cells per well. PC 12 cells were also plated in similar 
manner on laminin-coated (lOjxg/ml; GIBCO-BRL) glass cover slips. Transaction was 
performed using either Lipofectamin (PC 12 cells) or Effectin reagent (NIH 3T3 and COS7 
cells)(GIBCO-BRL) as described by the manufacture (Effectin) or using customized 
conditions. Lipofectamin transaction for a 12 well plate used 3.6(ig total DNA in 36pl 
serum free media mixed with 3.6jj1 lipofectamin in 36pl serum free medium for 20 minutes 
at room temperature, then the total mixture was mixed with 0.3 ml serum free medium and 
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added to one well. An additional 0.4 ml of serum free media was added to each well, and, 4 
hours later, all medium was replaced with regular culture medium. For Sari sequential DNA 
transaction, only Sari DNA was used for the first transaction, and after 18 hours a second 
round transaction was performed. For Sari co-transfection, a DNA ratio of 2:1 (Sari: other 
DNAs,) was used. For all other co-transfections a 1:1 DNA ratio was used (|xg). 
Brefeldin A, Nocodazole Treatment and Cycloheximide Clamp At 6 hours after 
transaction, Brefeldin A (BFA, 5pg/ml) was applied to the cells in regular medium. Cells 
were fixed and visualized by immuno-fluorescence at 30, 60 and 90 minutes after BFA 
treatment. For the cycloheximide clamp, cells were treated with cycloheximide (50|a.g/ml) 
immediately after the transaction. After 6 hours, cycloheximide was washed out and either 
BFA or nocodazole (20[xg/ml) was added to the medium. After 3 hours, cells were checked 
by immuno-fluorescence. For the cycloheximide double clamp experiment, cells were 
transfected and treated with cycloheximide for 6 hours, as before, then were rinsed to wash 
out the cycloheximide, and nocodazole was applied for 4 hours. Then nocodazole was 
washed out, and cycloheximide was added to the medium again. After 2 more hours, cells 
were fixed and stained for immunofluorescence. 
Immuno fluorescence Imaging NIH 3T3, COS7 or PC 12 cells were cultured, 
transfected and treated as described before. Cells were fixed with either 4% 
paraformaldehyde in phosphate-buffered saline (PBS) at room temperature for 15 minutes or 
100% methanol at -20°C for 30 minutes (for YFP-Secl3 transfected cells only).Cells were 
permeabilized with 0.2% TritonX-100 on ice for 5 minutes and quenched with 50mM 
NH4CI in PBS for 15 minutes at room temperature. For methanol fixation, there were no 
permealization and quench steps). After that, cells were incubated with blocker buffer (1% 
fat free milk in PBS) for 15 minutes at room temperature and then were incubated with 
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primary antibody for 1 hour at room temperature. After the primary antibody incubation, 
cells were washed with PBS once and incubated with secondary antibody for another 1 hour 
at room temperature. All the antibodies were diluted in blocker buffer. After the secondary 
antibody treatment, the cover slips were washed with PBS, distilled water, mounted on glass 
slides with mounting media (VECTASHELD) and rimmed with nail polish. Slides were 
examined and images were taken with either a Leica confocal microscope or Leica inverted 
fluorescence microscope (Model DIMER2). Images were contrast-enhanced, deconvolved 
and merged as indicated, using Improvision OpenLab software or Adobe Photoshop 
software. 
Counting Cells NIH 3T3 cells were co-transfected with DNAs for YFP-GT46 and H-
Ras wild type, H-RasQ61L mutant, or GFP-H-Ras tail. After 18 hours, cells were fixed and 
viewed by epifluorescence (for GFP constructs) or immuno-stained with H-Ras antibody.(H-
Ras). One hundred cells that expressed YFP-GT46 in the perinuclear area were then 
counted, and the number of cells in which H-Ras was present on plasma membrane or 
coincident with the perinuclear YFP-GT46 was noted. Three individual counts were 
performed and the data were analyzed using the Prism software program. 
Immuno-blot NIH 3T3 cells were transfected with DNA encoding H-RasQ61L and 
were treated with cycloheximide immediately for 6 hours. Cycloheximide was washed out, 
and BFA was added in the medium for 90 minutes. Cells were then lysed with 2X SDS-
PAGE loading buffer(l% SDS, 20% Glycerol, 200mM DTT, 10% 2-mercaptoethanol, 
0.04% Bromophenol Blue, 20mM Sodium Phosphate pH7.0) and boiled for 10 minutes. 
After separation by SDS-PAGE, proteins were transferred electrophoretically to 
polyvinylidene difluoride (PVDF) membrane, and non-specific protein binding was blocked 
by incubating the membrane in casein (Vector Laboratories) buffer diluted in TTBS buffer 
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(150mM NaCI, 50mM Tris pH7.4, 0.05% Tween 20). Membranes were probed with primary 
antibodies for H-Ras, Phospho-ERK or total ERK. HRP-conjugated secondary antibody was 
used and blots were developed with SuperSignal using the manufacturer's protocol 
(PIERCE). 
Results 
A majority of cells show accumulation of H-Ras protein only at the plasma membrane 
Earlier studies clearly documented the presence of H-Ras on the ER and Golgi, but 
gave no estimate of the percentage of cells displaying internal H-Ras. In addition, GFP-H-
Ras fusion proteins were used, which produce bright local signals that give a preferential 
impression of Golgi localization, making it difficult to determine the portion of protein on 
plasma membranes. When a non-tagged version of H-Ras and an H-Ras antibody were used, 
it was noted that many transfected NIH 3T3 cells showed H-Ras protein only on the plasma 
membrane and not on perinuclear membranes. To quantify the proportion of cells showing 
H-Ras staining on Golgi membranes, the YFP-GT46 protein, which traffics through the 
conventional secretory pathway, was co-expressed and visualized to verily the location of 
the Golgi apparatus. At 24 hr after transaction, when the amounts and locations of both 
YFP-GT46 and H-Ras were stable, YFP-GT46 was detectable in an organized perinuclear 
area (Golgi) in >90% of the transfected cells (Fig. 1 a.). One hundred cells that expressed 
YFP-GT46 in the perinuclear area were then counted, and the presence of H-Ras on plasma 
membrane or coincident with the perinuclear YFP-GT46 was noted in each. For the 
transfected cellular form of H-Ras (H-Ras-WT) (Histogram 1) -70% of the transfected cells 
showed H-Ras only at the plasma membrane, with none visible in the Golgi area marked by 
the YFP-GT46 (Fig. 1 b). A similar limitation in Golgi expression of H-Ras has been 
reported in CHO-K1 cells (Gomez). To see if a GTP-bound, oncogenic form of H-Ras 
behaved similarly, an activated version, H-Ras61L was transfected. Again, -70% of cells 
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showed no colocalization of H-Ras61L with the perinuclear GT46, although the plasma 
membrane was strongly illuminated. Some H-Ras proteins also showed a perinuclear 
structure that differed from that illuminated by GT46 (Fig.l b.). To examine if these 
perinuclear structures were Golgi, a Golgi resident protein (giantin) was used to mark the 
czs-Golgi structure. Although some H-Ras proteins appeared on the Golgi structure marked 
by giantin, some H-Ras proteins were present in a perinuclear structure that did not co-align 
with Golgi very well (Fig. 1 c.). These results suggested two possibilities: a) that in 70% of 
the cells the transit of H-Ras through internal membranes was so efficient that detectable 
amounts did not accumulate; or b) that a significant amount of H-Ras might be able to 
access the plasma membrane without utilizing the exocytic pathway through the Golgi. 
BFA treatment of cells does not trap H-Ras in the ER 
To test the hypothesis of efficient transport through Golgi membranes, brefeldin A was 
used to inhibit vesicular transport and cause Golgi collapse. Cells were transfected with 
cDNAs for HRasôlL and YFP-GT46, and were immediately treated with cycloheximide. 
After 6 hr for RNA synthesis, protein synthesis was permitted by washing out the 
cycloheximide, and brefeldin A (BFA) was added. After an additional 30 minutes, the cells 
were fixed and imaged. As expected for a transmembrane protein in the secretory pathway, 
YFP-GT46 became trapped in the ER after BFA treatment, and clearly outlined the ER 
membranes around the nucleus (Fig. 2a.). No other internal membranes contained YFP-
GT46, confirming that the Golgi apparatus had been absorbed into the ER. In contrast, H-
Ras61L continued to illuminate the plasma membrane in the presence of BFA (Fig. 2b.) No 
organized, Golgi-like structures that contained H-Ras61L were visible, and H-Ras61L 
showed no co-localization with the YFP-GT46, and no staining of the nuclear envelope. H-
Ras61L did illuminate some scattered internal membranes that did not have the layered 
appearance of Golgi, and seemed to be fluid-filled pinosomes, with H-Ras-stained rims but 
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dark interiors. Activation of H-Ras is known to strongly stimulate fluid-phase endocytosis 
[34], so these structures may be the recently reported H-Ras61 L-containing endocytic 
vesicles that were internalized after reaching the plasma membrane [35]. 
A second trial with a 3 hr exposure to BFA was performed to examine if H-Ras might 
accumulate on ER membranes if given more time. Even with this longer treatment, both H-
Ras wt and H-Ras 61L continued to move to the plasma membrane. Also, BFA added to 
cells at 18 hours after transaction caused no inhibition of steady state trafficking of H-Ras 
(data not shown). Additional experiments with H-Ras61L expressed in COS-7 cells showed 
that H-Ras61L movement to the plasma membrane was not interrupted by BFA in these 
other cell types as well (data not shown). Thus, even though H-Ras was visibly present on 
Golgi membranes in about 30% of (untreated) cells, those cells did not accumulate H-Ras 
internally during treatment with BFA. These results suggest that H-Ras can be transported to 
the plasma membrane using a pathway that does not need a functional Golgi. 
To determine if the activation state of the protein influenced whether H-Ras transport 
was BFA-insensitive, the experiments were repeated using the inactive, cellular form of H-
Ras (H-Ras-WT). The results were similar to those with the activated form. BFA had no 
inhibitory effect on movement of H-Ras-WT to the plasma membrane (Fig. 2c. (GT46) and 
2d. (WT)). These results indicated that neither GDP-bound nor GTP-bound forms of H-Ras 
require physically distinct Golgi membranes or an assembled COP I complex in order to 
travel to the cell surface. 
If the 10 C-terminal amino acids of H-Ras are appended to the C-terminus of GFP, the 
GFP-H-tail protein becomes lipid modified and can follow a pathway similar to that of the 
full-length H-Ras protein, from ER to Golgi to plasma membrane. This indicates that the C-
terminal domain of H-Ras is a major contributor to the interactions that produce H-Ras 
Golgi trafficking. This GFP-H-tail construct also showed two distributions in cells. About 
30% of cells that expressed GFP-H-tail showed protein only at the plasma membrane. The 
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remainder had protein present in both the Golgi and plasma membrane (Fig. 2e.). Because 
the GFP-H-tail protein marked Golgi membranes efficiently, the effect of BFA on movement 
of this protein was studied. Interestingly, when BFA was present, the GFP-H-tail protein 
arrived at the plasma membrane without problem (Fig. 2f.), and showed no evidence of 
accumulation on ER or nuclear envelope membranes. Thus, the 10 C-terminal amino acids 
of H-Ras can target GFP to internal membranes, and are also sufficient to confer BFA-
insensitive plasma membrane trafficking. 
Much of newly synthesized H-Ras moves rapidly and directly from ER to plasma 
membrane 
From the results above, it appeared that H-Ras might be able to use two parallel 
pathways for movement to the plasma membrane at steady state. To learn if one pathway of 
H-Ras movement was used preferentially prior to establishment of steady state, H-Ras travel 
from the ER outward was examined at early time points. For this, cells were co-transfected 
with cDNAs for H-Ras 61L and YFP-GT46 and then were placed in the medium containing 
cycloheximide for 6 hours to allow the cDNAs to be transcribed and the RNA for H-Ras to 
accumulate, but to prevent translation. Cycloheximide was then removed to produce a 
synchronous wave of H-Ras protein synthesis and trafficking. At various time points after 
cycloheximide removal, cells were fixed and imaged. Within 50 minutes of removal of 
cycloheximide, both H-Ras and YFP-GT46 were translated, correctly folded, and 
accumulated in amounts sufficient to be visible. At that time both proteins were present only 
on the ER (Fig. 3a. and b.). Twenty minutes later (70 minutes after cycloheximide removal) 
a strong signal of YFP-GT46 was present on well-organized perinuclear Golgi membranes in 
90% of the transfected cells (Fig. 3c.). H-Ras was present on perinuclear membranes that co-
localized with GT46 in 49% of the cells. Importantly, no visible GT46 had yet reached the 
plasma membrane. In contrast, H-Ras was now detectable on the cell surface, well ahead of 
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GT46 (Fig. 3d.). Approximately half of the cells that expressed H-Ras showed protein only 
at the plasma membrane. 
By 90 minutes after cycloheximide removal YFP-GT46 was present in the Golgi and, in 
some cells, on vesicles that appeared to be exiting the Golgi, but were not yet at the cell 
surface (Fig. 3e.). H-Ras was now easily visible at the plasma membrane, although the 
density of protein was still low enough that the distribution was not yet uniform and 
remained somewhat punctate (Fig. 3f.). H-Ras could also be seen on perinuclear membranes 
in 44% of the cells. Importantly, when the images were merged, some of the vesicles 
containing YFP-GT46 also had H-Ras. This agrees with previous reports that H-Ras traffics 
to the plasma membrane on vesicles [1, 36, 37]. 
Between 110 and 130 minutes after cycloheximide removal, GT46 reached the plasma 
membrane. At the latter time, H-Ras could be found at the plasma membrane and in GT46-
marked perinuclear membranes (Golgi) in 24% of the cells. These results indicated that there 
may be a slightly higher initial percentage of cells showing H-Ras on Golgi membranes and 
a decline to a proportion equivalent to steady state within 2 hours. Because the portion of 
cells showing H-Ras in a Golgi-like structure declined rather than increased, this indicates 
that the pathway through the Golgi does not represent an artefact of protein over-expression 
or a "backlog" of protein unable to move to the plasma membrane by the other pathway. 
Moreover, at every time point, both distributions were present. This suggests that both 
proposed pathways are used continuously for H-Ras transport. 
Disruption of ER exit sites does not prevent H-Ras traffic to the plasma membrane 
The results with BFA suggested that H-Ras does not require vesicular transport to leave 
the ER, but these studies inhibited only the COP I side of this process. This hypothesis was 
tested in a second way by preventing assembly of the COP II complex with mutants of the 
assembly regulator, Sari. Cells were co-transfected with cDNAs for H-Ras61L and Sari-
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T39N-HA, a GDP-bound inhibitory form of Sari, and 24 hr later were fixed and imaged. 
The H-Ras61L protein strongly outlined the plasma membrane of cells that over-expressed 
the Sari dominant negative protein (Fig. 4a.). There was no indication of accumulation of 
HRasôlL in the ER or around the nuclear envelope, nor any Golgi-like structures. This 
suggested indirectly that the Sarl-T39N had successfully ablated the Golgi. A second, longer 
experiment was also performed to give the Sarl-T39N more time to amass to levels that 
would certainly disrupt ER exit sites (ERES). Even after 48 hr, in cells co-expressing Sarl-
T39N and H-Ras61L, the Il-Ras61L continued to mark the plasma membrane and showed 
no build-up in the ER (data not shown). In addition, a sequential transaction technique was 
developed to allow Sari more time to become functional before H-Ras61L was expressed. 
Cells were first transfected with cDNA for the Sarl-T39N and allowed to express this 
protein for 18 hr. The cells were then transfected a second time with cDNA for H-Ras61L 
and after a further 24 hr, were fixed and imaged. All cells that expressed H-Ras61L showed 
strong plasma membrane staining, including those that also co-expressed the previously 
synthesized Sarl-T39N (Fig. 4b.). In cells that expressed both Sari-T39N and HRasôlL 
proteins, there was no Golgi-like staining of H-Ras61L on internal membranes. In cells that 
expressed only H-Ras61L or that had a lower expression of Sarl-T39N, there was again a 
mixture of cells displaying H-Ras on plasma membrane only, or having H-Ras on both 
plasma membrane and perinuclear membranes Fig. 4b shows two cells. One has strong Sarl-
T39N expression and in that cell there is no Golgi-like stain of H-Ras61L. Above this cell 
there is another cell, which has lower expression of Sarl-T39N, and in that cell H RasôlL is 
seen on both plasma membrane and the Golgi like perinuclear structure. To ensure that the 
Sarl-T39N protein was functioning correctly, a similar experiment was performed using the 
YFP-GT46 protein. The mutant Sari prevented YFP-GT46 from trafficking to the plasma 
membrane and caused it to accumulate on internal ER and nuclear envelope membranes 
(Fig. 4c.). This indicated that the amount of Sarl-T39N that was expressed was sufficient to 
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block transport of a protein in the traditional exocytic pathway. Equivalent results were 
obtained with Sarl-T39N and H-Ras61L expression in COS-1 cells (data not shown), 
indicating that H-Ras trafficking is Sari-independent in other cell types. To disrupt exit site 
assembly at a separate point, a different, GTP-bound Sari mutant, Sarl-H79G-HA, was 
employed. With either simultaneous or sequential transaction protocols (Fig. 4d.) H-
Ras61L continued to reach the plasma membrane in cells that also expressed the Sarl-H79G 
protein. 
Little H-Ras is present at ER exit sites or in the intermediate compartment 
The previous experiments suggested that H-Ras was not dependent on traditional 
vesicular mechanisms for its release from the ER. However, it was possible that H-Ras 
would still depart at the areas of the ER that are specialized for vesicle budding. To visualize 
these ER domains, the cellular form of H-Ras, H-Ras-WT, was co-expressed with YFP-
Secl3, a protein of the COP II exit site complex. The Seel3 protein could be seen in 
numerous discrete spots, most prominently in the larger cellular volume surrounding the 
nucleus (Fig. 5a.). H-Ras-WT was also present in numerous, smaller spots (Fig. 5b). 
However, the H-Ras did not align with the spots of YFP-Secl3, and showed a more even 
distribution throughout the cell, with little central accumulation (Fig. 5c). These results 
suggested that the H-Ras transport system does not utilize ER exit sites. 
Very few vesicles carrying H-Ras move to plasma membrane when Golgi is not 
available 
The results to this point suggested that H-Ras can use an alternative pathway to traffic to 
the plasma membrane, and that this pathway is independent of the classical vesicular route 
through the Golgi. To examine if this alternative pathway is also vesicular, or if it might be 
non-vesicular, a movie was recorded to study if any vesicles carrying H-Ras protein could be 
37 
seen moving to the plasma membrane when the Golgi was not available. NIH 3T3 cells were 
transfected with GFP-H-Ras61L DNA and treated with cycloheximide immediately after the 
transaction. After 6 hours, cycloheximide was washed out and BFA was added to the 
medium. After another 60 minutes to allow protein synthesis, movement of the GFP-H-
Ras61L was recorded at 90 seconds intervals for 2 hours. At 1 hour after the wash out of 
cycloheximide, GFP-H-Ras61L has already appeared on the ER membrane and is also 
present as dots within the cell. However, the GFP-H-Ras61L dots moved randomly inside 
the cell, and had no specific direction towards the plasma membrane (movie). Although a 
few dots (two dots in total 8 movies) did fuse with the plasma membrane and illuminate the 
membrane temporarily, the general absence of directed movement suggested that in BFA-
treated cells the alternative pathway for H-Ras movement to the plasma membrane is non­
vesicular. 
H-Ras accumulates at ERGIC when the classical pathway is blocked 
Even in the presence of BFA, GFP-H-Ras61L was often found on a bright perinuclear 
area. Similar results were found also with non-GFP versions of H-Ras proteins. This bright 
perinuclear area is obviously not a Golgi, since the Golgi will be absorbed into the ER 
within 30 minutes in the presence of BFA. An additional location associated with 
trafficking from ER to the Golgi is the series of COP II-regulated vesicular-tubular 
membranes that bud off ER exit sites and move toward the Golgi. These membranes are 
often termed the intermediate compartment (ERGIC) [38, 39]. ERGIC membranes are BFA-
resistant, are maintained rather than absorbed, and even accumulate in BFA-treated cells 
[39]. A reasonable hypothesis is that this BFA-resistant perinuclear structure is the ERGIC. 
This possibility was confirmed by an experiment which showed that H-Ras co-localized very 
well with an ERGIC marker protein, ERGIC-53, in COS7 cells that had been treated with 
BFA (Fig 6). 
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Since vesicular transport is dependent on microtubules, disruption of microtubules will 
interrupt the vesicular traffic. Previous work [36] had shown that H-Ras could reach the 
Golgi when microtubules were depolymerized by acute application of nocodazole. To 
determine if targeting of H-Ras to the plasma membrane was also independent of 
microtubules, cells expressing H-Ras were treated with nocodazole for 2 hours. With this 
treatment length, nocodazole causes fragmentation of the Golgi into multiple individual 
mini-Golgi stacks throughout the cell. These stacks were visualized with antibody to the 
endogenous Golgi protein, giantin, which verified that the nocodazole treatment had 
successfully dispersed the Golgi (Fig. 7a.). In these cells H-Ras61L showed partial co-
localization with giantin, in agreement with the previous report [36]. More importantly, in 
cells in which microtubules had been depolymerized, H-Ras61L could still move to the 
plasma membrane (Fig. 7b. c.). This indicated that the alternative pathway for H-Ras 
movement to the plasma membrane was probably non-vesicular or at least was not 
microtubule-dependent. Microtubule de-polymerization can interrupt vesicular transport 
both from ER/ERGIC to Golgi and from Golgi back to the ER. However, microtubule 
disruption does not interrupt traffic from ER to ERGIC, since ERGIC is formed by direct 
membrane budding from ER. Thus, nocodazole should not prevent H-Ras from getting to the 
ERGIC. To examine if some HRas was present in the ERGIC in nocodazole-treated cells, 
transfected COS7 cells were treated with cycloheximide for 6 hours, then with nocodazole 
for 3 hours in the absence of cycloheximide, and finally, were fixed and stained. Again the 
prediction was confirmed by the experimental data (Fig7 d.-f.) that showed H-Ras does co-
localize with ERGIC 53 in the nocodazole-treated cells. 
H-Ras is exported from ER directly when using the non-classical pathway 
Since it appears that H-Ras can move to the plasma membrane via a non-vesicular 
pathway or microtubule-independent pathway, it is important to understand where the export 
39 
site for H-Ras departure from the ER is located. There are three possibilities: a) H-Ras is 
exported directly from the ER; b) since H-Ras cannot be prevented from moving to the 
ERGIC either by BFA or by nocodazole, it is also possible that H-Ras is exported from 
ERGIC; or c) H-Ras is exported from both sites. To test these hypotheses, COS7 cells were 
first transfected and cycloheximide treated immediately. After 6 hours, cycloheximide was 
washed out to generate synchronous production of nascent H-Ras proteins. Nocodazole was 
added at that same time to allow these nascent H-Ras proteins get into but not get out of the 
ERGIC. After 4 hours, when a detectable portion of H-Ras protein accumulated in the 
ERGIC, a second cycloheximide treatment was applied to prevent new protein synthesis. 
Thus, only pre-existing H-Ras proteins are in the ERGIC, and no new proteins could move 
in. Therefore, if H-Ras can be exported from ERGIC via a non-vesicular pathway, one 
would expect that H-Ras would disappear from the ERGIC, since there would be no new H-
Ras supplied from the ER. However, this was not observed. H-Ras was still present in the 
ERGIC 2 hours after the second cycloheximide treatment (Fig 8 a. b. c.). In a control 
experiment, upon the second cycloheximide exposure, nocodazole was washed out, to now 
allow vesicular traffic out of the ERGIC. In this situation, H-Ras disappeared from the 
ERGIC membranes (data not shown). This results leaves only one possibility: H-Ras is 
exported from ER directly. 
Discussions 
Although Ras proteins were discovered in the 1960s [10-14], the issue of Ras protein 
transportation has not been carefully studied until in recent years, and even now, only H- and 
N-Ras protein trafficking to the plasma membrane is somewhat illuminated [40]. The results 
from these previous studies showed that shortly after synthesis, H- and N-Ras are attached to 
the ER and then moved to the Golgi. From the Golgi, H- and N-Ras are transported to the 
plasma membrane by vesicles. These conclusions are drawn largely from the observations 
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that GFP-fused chimeric H- or N-Ras proteins are associated with ER and Golgi and appear 
on the exocytic pathway. Low temperature can cause H-Ras and N-Ras to accumulate in the 
Golgi, and BFA can largely inhibit them from getting to the plasma membrane. In this study, 
we compared H-Ras transportation through the classical vesicular pathway and found that H-
Ras traffic to plasma membrane is quite different from the conventional pathway. H-Ras 
proteins are not associated with Golgi at steady state; the velocity of H-Ras transportation to 
plasma membrane is much faster than YFP-GT46, a protein that uses the typical 
conventional vesicular pathway. Also, H-Ras transportation to the plasma membrane cannot 
be blocked by either Sarl-T39N or BFA, whereas YFP-GT46 movement is inhibited. This 
means that H-Ras traffic to the plasma membrane can be independent of ER to Golgi 
transport mediated either by COPII-coated or COPI-coated vesicles. These combined results 
lead us to propose that a significant amount of H-Ras uses a non-classical pathway for 
transportation to the plasma membrane. In NIH 3T3 cells, this non-classical pathway appears 
to be the primary means for plasma membrane access. In COS-7 cells, the conventional 
vesicular pathway appears to be more prominent (unpublished data). Thus, H-Ras has two 
pathways by which it can reach the plasma membrane, and appears to use both 
simultaneously. Similar to what we report here, a previous report has shown that a yeast Ras 
protein may also move to the plasma membrane using a non-classical pathway [41]. This 
indicates this non-classical pathway may be conserved in eukaryotes. 
This non-classical pathway appears to be initiated at the ER rather than the Golgi. 
Comparison of the localizations of H-Ras and Sec 13 on ER membranes suggests that very 
little H-Ras leaves via conventional vesicle budding domains of ER export sites. In addition, 
once H-Ras has entered the conventional vesicular transport pathway, it has very limited 
access to this non-classical pathway. 
Though the two different pathways for H-Ras traffic diverge even as early as on the ER, 
it is not clear what makes this divergence happen. One possible mechanism is 
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palmitoylation. There is existing evidence that, as long as it is non-palmitoylated, 
farnesylated H-Ras is in a dynamic equilibrium between the cytosol and membranes [24]. 
Once H-Ras encounters a membrane-bound palmitoyl transferase and becomes 
palmitoylated, it can no longer escape from that membrane, and at that point the 
palmitoylated H-Ras joins the classical vesicular pathway [36, 37]. A possibility suggested 
by our results is that if H-Ras is not palmitoylated on the ER, it will use the non-classical 
pathway to move to the plasma membrane and there will become palmitoylated. There is 
already some evidence that supports the possibility of H-Ras palmitoylation on the plasma 
membrane. A novel H-Ras that is not farnesylated but that retains the native cysteines as 
sites for acylation, completely avoids the Golgi, yet is targeted to the plasma membrane and 
becomes palmitoylated [42]. 
In both yeast and mammalian cells, the non-classical pathway for Ras transport can 
function in the apparent absence of vesicles. In NIH 3T3 mouse fibroblasts, neither 
interruption of all vesicular transport with nocodazole nor live cell movies of BFA-treated 
cells provided any evidence for vesicles that might carry H-Ras to plasma membrane. Thus, 
the data currently suggest that this non-classical pathway is non-vesicular. There are two 
possible mechanisms for this non-vesicular transportation. One is simple diffusion, which is 
a mechanism K-Ras may also use. However, this would expose the hydrophobic farnesyl 
(and possibly palmitoyl) group at the C-terminus of H-Ras to the aqueous phase. This 
situation would be thermodynamically unfavorable unless the lipid groups were able to fold 
back against the protein. There is currently no precedent for such a model. Another 
possibility is for some chaperon proteins to interact with the C-terminus and mask the 
hydrophobic tail of H-Ras. A very recent report on potassium channel interacting proteins 
(KChlPs) may shine light on this issue. In this report, the authors found KChlPs can help the 
Kv4 class of voltage-gated K+ channels to localize on the plasma membrane. In the absence 
of KchlPs the Kv4 channels are retained on ER and Golgi membranes. The pathway utilized 
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by the KchIP:Kv4 complex is a non-COPII-coated vesicular pathway [40]. This is one of the 
few examples of Sari-independent plasma membrane trafficking. H-Ras proteins may also 
need some proteins like KChlPs to help them get out to the plasma membrane when using 
the non-classical pathway. 
Ras protein mutations are frequently found in human tumor cells and several cancer 
therapies currently in clinical trials are designed to inhibit membrane binding of Ras proteins. 
Although these drugs may be targeted at reducing the abundance of H-Ras on the plasma 
membrane, our findings that H-Ras may use two pathways for its plasma membrane 
transportation suggests that there are more difficulties to be overcome before this therapeutic 
strategy will be successful. 
References 
1. Choy, E., et al., Endomembrane trafficking of Ras: the CaaX motif targets proteins to 
the ER and Golgi. Cell, 1999. 98: p. 69-80. 
2. Roy S, P.S., Rotblat B, Prior LA, Muncke C, Grainger S, Parton RG, Henis YI, Kloog 
Y, Hancock JF, Individual palmitoyl residues serve distinct roles in H-ras trafficking, 
microlocalization, and signaling. Mol Cell Biol, 2005. 25(15): p. 6722-33. 
3. Apolloni, A., et al., H-ras but not K-ras traffics to the plasma membrane through the 
exocyticpathway. Mol. Cell. Biol., 2000. 20: p. 2475-2487. 
4. Zhang, L., W.R. Tschantz, and P.J. Casey, Isolation and characterization of a 
prenylcysteine lyase from bovine brain. J. Biol. Chem., 1997. 272: p. 23354-23359. 
5. Hightower, K.E., C.-c. Huang, and C.A. Fierke, H-Ras peptide and protein 
substrates bind protein farnesyltransferase as an ionized thiolate. Biochemistry, 
1998.37: p. 15555-15562. 
6. Hancock, J.F., et al., A CAAX or a CAAL motif and a second signal are sufficient for 
plasma membrane targeting of ras proteins. EMBO J., 1991. 10: p. 4033-4039. 
43 
7. Hancock, J.F., H. Paterson, and C.J. Marshall, A polybasic domain or palmitoylation 
is required in addition to the CAAX motif to localize p2 Iras to the plasma membrane. 
Cell, 1990. 63: p. 133-139. 
8. Schroeder, H., et al., S-acylation and plasma membrane targeting of the farnesylated 
carboxy-terminal peptide ofN-ras in mammalian fibroblasts. Biochemistry, 1997. 30: 
p. 13102-13109. 
9. Willumsen, B.M., et al., Novel determinants of H-Ras plasma membrane localization 
and transformation. Oncogene, 1996. 13: p. 1901-1909. 
10. Figueroa, C., J. Taylor, and A.B. Vojtek, Prenylated Rab acceptor protein is a 
receptor for prenylated small GTPases. J. Biol. Chem., 2001. 276: p. 28219-28225. 
11. Hanzal-Bayer, M., et al., The complex of Arl2-GTP and PDES: from structure to 
function. Embo J, 2002. 21: p. 2095-2106. 
12. Ghomashchi, F., et al., Binding ofprenylated and polybasic peptides to membranes: 
affinities and intervesicle exchange. Biochemistry, 1995. 34: p. 11910-11918. 
13. Wang, T.-Y., R. Leventis, and J R. Silvius, Partitioning oflipidatedpeptide 
sequences into liquid-ordered lipid domains in model and biological membranes. 
Biochemistry, 2001. 40: p. 13031-13040. 
14. Roy, M. O., R. Leventis, and J R. Silvius, Mutational and biochemical analysis of 
plasma membrane targeting mediated by the farnesylated, polybasic carboxy 
terminus of K-ras4B. Biochemistry, 2000. 39: p. 8298-8307. 
15. Silvius, JR., Mechanisms of Ras protein targeting in mammalian cells. J. Membrane 
Biology, 2002. 190: p. 83-92. 
16. Fivaz M, M.T., Reversible intracellular translocation of KRas but not HRas in 
hippocampal neurons regulated by Ca2+ /calmodulin. J Cell Biol, 2005. 170(3): p. 
429-41. 
44 
17. Smotrys JE, L.M., Palmitoylation of intracellular signaling proteins: regulation and 
function. Annu Rev Bioc, 2004. 73: p. 559-587. 
18. Swarthout JT, L.S., Farh L, Croke MR, Greentree WK, Deschenes RJ, Linder ME, 
DHHC9 and GCP16 constitute a human protein fatty acyltransferase with specificity 
for H- and N-Ras. J Biol Chem, 2005. 280(35): p. 31141-8. 
19. Magee T, S.M., Fatty acylation and prenylation ofproteins: what's hot in fat. Curr 
Opin Cell Biol, 2005. 17(2): p. 190-6. 
20. Huang K, Y.A., Kang R, Arstikaitis P, Singaraja RR, Metzler M, Mullard A, Haigh 
B, Gauthier-Campbell C, Gutekunst CA, Hayden MR, El-Husseini A, Huntingtin-
interacting protein HIP 14 is a palmitoyl transferase involved in palmitoylation and 
trafficking of multiple neuronal proteins. Neuron, 2004. 44(6): p. 977-86. 
21. Ducker CE, S.E., French KJ, Upson JJ, Smith CD, Huntingtin interacting protein 14 
is an oncogenic human protein: palmitoyl acyltransferase. Oncogene, 2004. 23(57): 
p. 9230-7. 
22. Booden, M.A., et al., A non-farnesylated HRas protein can be palmitoylated and 
trigger potent differentiation and transformation. J. Biol. Chem, 1999. 274: p. 1423-
1431. 
23. Dong, S., et al., Palmitoylation and plasma membrane localization of Ras2p by a 
nonclassical trafficking pathway in Saccharomyces cerevisiae. Molecular and 
Cellular Biology, 2003. 23: p. 6574-6578. 
24. Sang SL, S.J., Novel thioester reagents afford efficient and specific S-acylation of 
unprotected peptides under mild conditions in aqueous solution. J Pept Res, 2005. 
66(4): p. 169-80. 
25. Miller, E.A., et al., Multiple cargo binding sites on the COP1I subunit Sec24p ensure 
capture of diverse membrane proteins into transport vesicles. Cell, 2003. 114: p. 
497-509. 
45 
26. Antonny, B. and R. Schekman, ER export: public transportation by the COPII coach. 
Current Opinion in Cell Biology, 2001. 13: p. 438-443. 
27. Matsuoka K, O.L., Amherdt M, Bednarek SY, Hamamoto S, Schekman R, Yeung T, 
COPIl-coated vesicle formation reconstituted with purified coat proteins and 
chemically defined liposomes. Cell, 1998. 93(2): p. 263-75. 
28. Aridor, M., et al., The Sari GTPase coordinates biosynthetic cargo selection with 
endoplasmic reticulum export site assembly. J. Cell Biol., 2001. 152: p. 213-229. 
29. Watanabe, R. and H. Riezman, Differential ER exit in yeast and mammalian cells. 
Current Opinion in Cell Biology, 2004. 16: p. 350-355. 
30. McMahon, H.T. and I.G. Mills, COP and clathrin-coated vesicle budding: different 
pathways, common approaches. Current Opinion in Cell Biology, 2004. 16: p. 379-
391. 
31. Bannykh SI, P H., Matteson J, Balch WE, The role of ARF1 and rab GTPases in 
polarization of the Golgi stack Traffic, 2005. 6(9): p. 803-19. 
32. Watson, R.T., et al., The exocytotic trafficking of TCI 0 occurs through both classical 
and nonclassical secretory transport pathways in 3T3L1 adipocytes. Mol. Cell. Biol., 
2003. 23: p. 961-974. 
33. O'Callaghan, D.W., et al., Residues within the myristoylation motif determine 
intracellular targeting of the neuronal Ca2+ sensor protein KChlPl to post-ER 
transport vesicles and traffic of Kv4 K+ channels. J Cell Sci, 2003. 116(23): p. 4833-
4845. 
34. Bar-Sagi D, F.J., Induction of membrane ruffling and fluid-phase pinocytosis in 
quiescent fibroblasts by ras proteins. Science, 1986. 233(4768): p. 1061-8. 
35. Gomez GA, D.J., H-Ras dynamically interacts with recycling endosomes in CHO-K1 
cells: involvement of Rab5 and Rabl 1 in the trafficking of H-Ras to this 
pericentriolar endocytic compartment. J Biol Chem, 2005. 280(41): p. 34997-5010. 
46 
36. Goodwin JS, D.K., Rogers C, Wright L, Lippincott-Schwartz J, Philips MR, 
Kenworthy AK, Depalmitoylated Ras traffics to and from the Golgi complex via a 
nonvesicular pathway. J Cell Biol, 2005. 170(2): p. 261-72. 
37. Rocks, O., et al., An acylation cycle regulates localization and activity of 
palmitoylated Ras isoforms. Science Express, 2005. 11 February 2005: p. 
10.1126/science.l 105654. 
38. Hauri, H.-P., et al., ERGIC-53 and traffic in the secretory pathway. J. Cell Science, 
2000. 113: p. 587-596. 
39. Breuza, L., et al., Proteomics of Endoplasmic Reticulum-Golgi Intermediate 
Compartment (ERGIC) Membranes from Brefeldin A-treated HepG2 Cells Identifies 
ERGIC-32, a New Cycling Protein That Interacts with Human Erv46. J. Biol. Chem., 
2004. 279(45): p. 47242-47253. 
40. Hasdemir B, F.D., Prior LA, Tepikin AV, Burgoyne RD, Traffic of Kv4 K+ channels 
mediated by KChlPl is via a novel post-ER vesicular pathway. J Cell Biol, 2005. 
171(3): p. 459-69. 
41. Lowy, D.R. and B.M. Willumsen, Function and regulation of Ras. Ann. Rev. 
Biochem., 1993. 62: p. 851-891. 
42. Coats, S.G., M.A. Booden, and J.E. Buss, Transientpalmitoylation supports H-Ras 
membrane binding but only partial biological activity. Biochemistry, 1999. 38: p. 
12926-12934. 
47 
Figure Legends 
Figure 1 a. YFP-GT46 was detectable in an organized perinuclear area (Golgi) in >90% of 
the transfected cells. NIH 3T3 cells were transfected with YFP-GT46 DNA. 18 hours after 
transaction, cells were fixed and examined by the fluorescent microscope. Arrowheads 
show the perinuclear area (Golgi). 
Histogram 1 30% H-Ras shows the perinuclear area (Golgi) co-aligned with YFP-GT46. 
NIH 3T3 cells were co-transfected with YFP-GT46 DNA and H-Ras wild type or Q61L 
mutant or GFP-H-Ras tail DNAs.18 hours after the transaction, cell were fixed and stained 
with antibodies (H-Ras). One hundred cells that expressed YFP-GT46 in the perinuclear 
area were then counted, and the numbers of H-Ras presents on plasma membrane or 
coincident with the perinuclear YFP-GT46 was noted. 100 cells were counted and three 
individual counts were performed and the data were analyzed by the Prisim software, error 
bar shows the standard error between three counts. 
Figure 1 b. -70% of the transfected cells showed H-Ras only at the plasma membrane, with 
none visible in the Golgi area marked by the YFP-GT46. NIH 3T3 cells were co-transfected 
with YFP-GT46 DNA and H-Ras wild type DNA. 18 hours after the transaction, cell were 
fixed and stained with antibodies (H-Ras) and then imaged. Arrowhead shows YFP-GT46 
labeled perinuclear (Golgi) structure. 
Figure 1 c. H-Ras wild type does not show much co-alignment with the Giantin labeled 
Golgi. COS7 cells were transfected with H-Ras wild type DNA. 18 hours after the 
transaction, cell were fixed and Immuno-stained then imaged. Arrowheads show the Golgi / 
perinuclear structure. 
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Figure 2 a. YFP-GT46 became trapped in the ER after BFA treatment, and clearly outlined 
the ER membranes around the nucleus. NIH 3T3 cells were transfected with YFP-GT46 
DNA, and then immediately treated with cycloheximide. After 6 hours cycloheximide was 
washed out, and brefeldin A (BFA) was added. 90 minutes after, cells were fixed and 
imaged. Arrowheads show the localization of the YFP-GT46. 
Figure 2 b. H-Ras 61L continued to illuminate the plasma membrane in the presence of 
BFA. NIH 3T3 cells were co-transfected with YFP-GT46 and H-Ras DNAs, and then 
immediately treated with cycloheximide. After 6 hours cycloheximide was washed out, and 
brefeldin A (BFA) was added. 90 minutes after, the cells were fixed and imaged. 
Arrowheads show the localization of the YFP-GT46 and H-Ras 61L. 
Figure 2 c. YFP-GT46 became trapped in the ER after BFA treatment, and clearly outlined 
the ER membranes around the nucleus. NIH 3T3 cells were transfected with YFP-GT46 
DNA, and then immediately treated with cycloheximide. After 6 hours cycloheximide was 
washed out, and brefeldin A (BFA) was added. 90 minutes after, cells were fixed and 
imaged. Arrowheads show the localization of the YFP-GT46. 
Figure 2 d. H-Ras wt continued to illuminate the plasma membrane in the presence of BFA. 
NIH 3T3 cells were co-transfected with YFP-GT46 and H-Ras DNAs, and then immediately 
treated with cycloheximide. After 6 hours cycloheximide was washed out, and brefeldin A 
(BFA) was added. 90 minutes after, the cells were fixed and imaged. Arrowheads show the 
localization of the YFP-GT46 and H-Ras 61L. 
Figure 2 e. About 70% GFP-H-Ras Tail is present in both the Golgi and plasma membrane. 
NIH 3T3 cells were transfected with GFP-H-Ras Tail DNA. 18 hours after transaction, cells 
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were fixed and examined by the fluorescent microscope. Arrowheads show the localization 
of the GFP-H-Ras Tail. 
Figure 2 f. With BFA present, the GFP-H-tail protein arrived at the plasma membrane 
without problem and showed no evidence of accumulation on ER or nuclear envelope 
membranes. NIH 3T3 cells were transfected with GFP-H-Ras Tail DNA and then 
immediately treated with cycloheximide. After 6 hours cycloheximide was washed out, and 
brefeldin A (BFA) was added. 90 minutes after, the cells were fixed and imaged. 
Arrowheads show the localization of the GFP-H-Ras Tail. 
Figure 3 a. and b. Within 40 minutes of removal of cycloheximide, both H-Ras and YFP-
GT46 were translated and were present mainly on the ER. NIH 3T3 cells were co-transfected 
with cDNAs for GFP-H-Ras and YFP-GT46 and then were placed in the medium containing 
cycloheximide for 6 hours. Cycloheximide was then removed. 20 minutes after 
cycloheximide removal, cells were fixed and stained for image. Arrowheads show the 
localization of either YFP-GT46 or H-Ras 61L. 
Figure 3 c. and d. 60 minutes after removal of cycloheximide, YFP-GT46 were was present 
mainly on the Golgi while H-Ras has already reached to the plasma membrane. NIH 3T3 
cells were co-transfected with cDNAs for GFP-H-Ras and YFP-GT46 and then immediately 
were clamped with cycloheximide for 6 hours. Cycloheximide was then removed. 40 
minutes after cycloheximide removal, cells were fixed and stained for image. Arrowheads 
show the localization of either YFP-GT46 or H-Ras 61L. 
Figure 3 e. 110 minutes after removal of cycloheximide, YFP-GT46 was present in the 
Golgi and, in some cells, on vesicles that appeared to be exiting the Golgi, but were not yet 
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at the cell surface. NIH 3T3 cells were co-transfected with cDNAs for GFP-H-Ras and YFP-
GT46 and then were placed in the medium containing cycloheximide for 6 hours. 
Cycloheximide was then removed. 90 minutes after cycloheximide removal, cells were fixed 
and stained for image. Arrowheads show the localization of either YFP-GT46 or H-Ras 61L. 
Figure 3 f. 110 minutes after removal of cycloheximide, H-Ras was now easily visible at the 
plasma membrane. NIH 3T3 cells were co-transfected with cDNAs for GFP-H-Ras and 
YFP-GT46 and then immediately were clamped with cycloheximide for 6 hours. 
Cycloheximide was then removed. 90 minutes after cycloheximide removal, cells were fixed 
and stained for image. Arrowheads show the localization of either YFP-GT46 or H-Ras 61L. 
Figure 3 g. Some of the vesicles containing YFP-GT46 also had H-Ras. NIH 3T3 cells were 
co-transfected with cDNAs for GFP-H-Ras and YFP-GT46 and then immediately were 
clamped with cycloheximide for 6 hours. Cycloheximide was then removed. 90 minutes 
after cycloheximide removal, cells were fixed and stained for image. Arrowheads show the 
vesicles have both GFP-H-Ras and YFP-GT46. 
Figure 4 a. The H-Ras61L protein strongly outlined the plasma membrane of cells that over-
expressed the Sari dominant negative protein. NIH 3T3 cells were co-transfected with Sarl-
T39N-HA and H-Ras 61L DNAs at 2:1 ratio (pg). 24 hours after transaction, cells were 
fixed and immuno-stained for image. Arrowheads show the localization of H-Ras 61L. 
Figure 4 b. All cells that expressed H-Ras61L showed strong plasma membrane staining, 
including those that also co-expressed the previously synthesized Sarl-T39N. NIH 3T3 cells 
were transfected with Sarl-T39N-HA DNA. 18 hours after transaction, same cells were 
51 
transfected again with H-Ras 61L DNA. 24 hours after the second transaction, cells were 
fixed and immuno-stained for image. Arrowheads show the localization of H-Ras 61L. 
Figure 4 c. The mutant Sari prevented YFP-GT46 from trafficking to the plasma membrane 
and caused it to accumulate on internal ER and nuclear envelope membranes. NIH 3T3 cells 
were co-transfected with Sarl-T39N-HA and YFP-GT46 DNAs at 2:1 ratio (fo.g). 24 hours 
after transaction, cells were fixed and immuno-stained for image. 
Figure 5 a. The Seel 3 protein is most prominently in the ER network surrounding the 
nucleus and also in numerous discrete spots. NIH 3T3 cells were co-transfected with YFP-
SEC13 and H-Ras 61L DNAs (1:1 ratio in jxg). 18 hours after transfection, cells were fixed 
and stained for image. 
Figure 5 b. H-Ras 61L was also present in numerous smaller spots. NIH 3T3 cells were co-
transfected with YFP-SEC13 and H-Ras 61L DNAs (1:1 ratio in jxg). 18 hours after 
transfection, cells were fixed and stained for image. 
Figure 5 c. H-Ras did not align with the spots of YFP-Secl3, and showed a more even 
distribution throughout the cell, with little central accumulation. NIH 3T3 cells were co-
transfected with YFP-SEC13 and H-Ras 61L DNAs (1:1 ratio in jxg). 18 hours after 
transfection, cells were fixed and stained for image. 
Figure 6 H-Ras accumulate in the ER-Golgi Intermedia Compartment (ERGIC) after long 
BFA treatment . NIH 3T3 cells were transfected with cDNAs for H-Ras61L and then 
immediately were clamped with cycloheximide for 6 hours. Cycloheximide was then 
removed. Upon the removal of cycloheximide BFA was added into the media, After 2 hour, 
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cells were fixed and stained for image. Arrowheads show the locations H-Ras61L and 
ERGIC. 
Figure 7 a. Golgi is dispersed as fragments after 3 hour of nocodazole treatment . COS7 
cells were transfected with cDNAs for H-Ras61L and then immediately were clamped with 
cycloheximide for 6 hours. Cycloheximide was then removed. Upon the removal of 
cycloheximide nocodazole was added into the media, After 3 hour, cells were fixed and 
stained for image. Arrowheads show the location of Golgi fragments. 
Figure 7 b. H-Ras61L continue moves to the plasma membrane in the microtubules de-
polymerized cells. COS7 cells were transfected with cDNAs for H-Ras61L and then 
immediately were clamped with cycloheximide for 6 hours. Cycloheximide was then 
removed. Upon the removal of cycloheximide nocodazole was added into the media, After 3 
hour, cells were fixed and stained for image. Arrowheads show the location of H-Ras61L 
proteins. 
Figure 7 c. H-Ras61L shows partial co-localization with Golgi fragments in the 
microtubules de-polymerized cells. COS7 cells were transfected with cDNAs for H-Ras61L 
and then immediately were clamped with cycloheximide for 6 hours. Cycloheximide was 
then removed. Upon the removal of cycloheximide nocodazole was added into the media. 
After 3 hour, cells were fixed and stained for image. Arrowheads show the co-localization of 
Golgi fragments and H-Ras61L. 
Figure 7 d. EGRIC53 shows as membrane particle fragments in the microtubules de-
polymerized cells. COS7 cells were transfected with cDNAs for H-Ras61L and then 
immediately were clamped with cycloheximide for 6 hours. Cycloheximide was then 
removed. Upon the removal of cycloheximide nocodazole was added into the media. After 3 
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hours, cells were fixed and stained for image. Arrowheads show the co-localization of 
GERIC. 
Figure 7 e. H-Ras61L shows both plasma membrane and internal particle-like membranes 
in the microtubules de-polymerized cells. COS7 cells were transfected with cDNAs for H-
Ras61L and then immediately were clamped with cycloheximide for 6 hours. Cycloheximide 
was then removed. Upon the removal of cycloheximide nocodazole was added into the 
media. After 3 hours, cells were fixed and stained for image. Arrowheads show the 
localization of H-Ras61L. 
Figure 7 f. H-Ras61L and ERGIC53 show co-localization in the nocodazole treated cells. 
COS? cells were transfected with cDNAs for H-Ras61L and then immediately were clamped 
with cycloheximide for 6 hours. Cycloheximide was then removed. Upon the removal of 
cycloheximide nocodazole was added into the media. After 3 hours, cells were fixed and 
stained for image. Arrowheads show the localization of H-Ras61L and ERGIC53. 
Figure 8 a. and b. H-Ras61L and ERGIC53 show a particle like membrane localization in 
the nocodazole and cycloheximide double clamped cells. COS? cells were transfected with 
cDNAs for H-Ras61L and then immediately were clamped with cycloheximide for 6 hours. 
Cycloheximide was then removed. Upon the removal of cycloheximide nocodazole was 
added into the media. After 4 hours, cells were clamped with cycloheximide again. After 
another 2 hour, cells were fixed and stained for image. Arrowheads show the localization of 
either H-Ras61L or ERGIC53. 
Figure 8 c. All the ERGIC membrane fragments have H-Ras61L on it. COS? cells were 
transfected with cDNAs for H-Ras61L and then immediately were clamped with 
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cycloheximide for 6 hours. Cycloheximide was then removed. Upon the removal of 
cycloheximide nocodazole was added into the media. After 4 hours, cells were clamped with 
cycloheximide again. After another 2 hour, cells were fixed and stained for image. 
Arrowheads show the localization of either H-Ras61L or ERGIC53. 
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Figure 2 a. 
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Figure 2 b. 
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Figure 2 e. 
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Figure 3 a. 
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Figure 3 b. 
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Figure 3 c. 
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Figure 3 d. 
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Figure 3 e. 
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Chapter 3: Two New C-terminal Variants of H-Ras that are Trapped on 
Endomembranes Show Similar Effector Interactions but Distinct 
Biological Activities 
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Abstract 
The amino acid residues in the carboxyl tail region play key roles in the traffic and 
membrane localization of H-Ras protein. Two H-Ras mutants SDQCE and CDQCE are 
found retained on the endomembranes and absent from the plasma membrane although they 
are proved or putative famesylated and palmitoylated. The mechanism for their entrapment 
on the endomembranes is conserved in many cell types. The endomembranes localization 
does not abolish their ability for effector binding. Although having similar membrane 
localization, the signal transductions generated by these two mutants are quite different 
which are reflected by the behaviors of transformed cells. Expression of these internal 
proteins in PC 12 cells showed that although they were competent to signal cell cycle arrest 
and to trigger differentiation, each had limitations that implied abnormalities in signaling. 
Both SDQCE and CDQCE signal transductions are different from that of wild type H-Ras. 
These proteins are the first palmitoylated forms of H-Ras that are trapped internally and 
demonstrate that effector interactions from this location can produce novel signaling 
outcomes. 
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Introduction 
Ras proteins are small monomelic guanine nucleotide binding proteins that play key 
roles in many signal transduction pathways that regulate cell proliferation, differentiation 
and apoptosis. Mammalian Ras proteins include four members, H-Ras, N-Ras, K-Ras4A and 
K-Ras4B [1],After translation, the nascent Ras peptides are recognized by a cytosolic 
famesyl transferase and are famesylated at the cysteine residue of their CAAX motif. After 
that, the famesylated Ras proteins bind to the cytosolic surface of the ER. On the ER 
membrane, the -AAX part is cleaved by a protease named RCE1 and leaves the carboxyl 
group of cysteine exposed for further modification. Then the isoprenylated cysteine residue 
is methylated by a methyl transferase called Icmt [2, 3]. After that H- and N-Ras are further 
palmitoylated by an acyl transferase that may localize at Golgi or ER. From Golgi H- and N-
Ras travel to the plasma membrane via a classical vesicular pathway while K-Ras may 
directly diffuse to the plasma membrane from ER [4], 
Plasma membrane is the major destination for Ras proteins targeting and the most 
important platform for Ras proteins signaling. Ras mutations that mis-localized on other 
membrane structures seem lost their biological functions. However recent studies from MR 
Philips group showed the plasma membrane is not the only place for Ras proteins signaling. 
H-and N-Ras regulated signal transduction events can also happen on ER and Golgi [5-7]. 
Although a more recent report showed evidence that plasma membrane may still be the 
predominant site for endogenous Ras signaling [8], a even more recent report showed K-
Ras4B, can even redirect from plasma membrane to mitochondrial membrane upon the PKC 
phosphorylation and signals from there to induce a cell apoptosis [9]. All these studies 
suggest there may be still a long way for people fully understand Ras signal transduction. 
Nevertheless, the studies on the compartmentalized Ras signaling is still very meaningful in 
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helping people to understand how a single Ras protein can regulate so many different signal 
pathways and thus generate various biological outcomes. 
Two H-Ras mutants, SDQCE and CDQCE were found to be permanently trapped on 
the ER and Golgi membranes. These two mutants provide an opportunity to study what is 
the difference between endomembranes based and plasma membrane based H-Ras signal 
events. We found although localized on the endomembranes, the oncogenic form of these 
two H-Ras mutants can still bind effector protein and show subtle different transforming 
potentials. We found that maybe by the different localizations, these two mutants can also 
induce different cell differentiation. 
Materials and Methods 
Plasmids and Antibodies H-Ras wild type, H-Ras Q61L, were expressed from pcDNA3 
(Invitrogen). The SDQCE and CDQCE mutation were generated by oligonucleotide-directed 
polymerase chain reaction (PCR). The 5' primer is 5'-
GGGGGGATCC ACC AT G AC AG AAT AC AAGCTT-3 ', which is fully complementary to 
the 5' sequence of human H-Ras. The mutagenic oligonucleotide 5'-
AT AG ACGT CTT AAGGATT GAATTAT GCGTAAGT G AAACT AGT GACGGCCCCG-G-
3'(CDQCE) and 5'-
AT AG ACGT CTTAAGGATT GAATT AT GCGTAAGT G AAACT AGT GTCGGCCCCG-G-
3'(SDQCE) were used as 3' primer for introducing a EcoRI site and Ras carboxyl terminal 
mutants. Ras monoclonal antibody 238 (Santa Cruz), Alexa Fluor 594 donkey anti-rat 
conjugate, Alexa Fluor 488 goat anti-rat conjugate antibodies and Alexa Fluor 594 
phalloidin (Molecular Probes) were used for immuno-fluorescence imaging. Ras monoclonal 
antibody 238 (Santa Cruz), and 146 (Quality Biotech) were used for immuno-precipitation, 
Ras monoclonal antibody pan (BD Transduction Laboratories), Rafl polyclonal antibody C2 
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(Upstate biotechnology), Pi-ERK monoclonal antibody (Cell Signaling), ERK1 polyclonal 
antibody K-23 (Santa Cruz), Pi-Akt monoclonal antibody (Cell Signaling), Akt polyclonal 
antibody (New England BioLabs) ImmunoPure Goat anti-mouse, Goat anti-rat, donkey anti-
rabbit and mouse anti-goat antibodies (PIERCE) were used for immuno-blot. 
Cell Culture and Transfection NIH 3T3, RATI and COS7 cells were cultured at 10% 
C02 in Dulbecco's Modified Eagle's Medium (GIBCO-BRL) supplemented with 10% calf 
serum (Hyclone Laboratories). PC 12 cells were maintained at 5% C02 in RPMT 1640 
medium supplemented with 10% heat-inactivated horse serum and 5% fetal calf serum (both 
from Hyclone Laboratories). Twenty-four hours before DNA transfection, NIH 3T3 cells and 
COS7 cells were plated on the pre-washed glass cover slips (Coming) in 12 well tissue 
culture plate at a density about 105-106 cells per well. PC12 cells were also plated in similar 
manner on the laminin-coated (10pg/ml; GIBCO-BRL) glass cover slips. Transfection was 
performed using either Lipofectamin (PC 12 cells) or Effectin reagent (NIH 3T3 and COS7 
cells)(GIBCO-BRL) as described by the manufacture (Effectin) or customized condition 
(Lipofectamin for 12 well plate, 3.6pg total DNA in 36(0.1 serum free media was mixed with 
3.6(j,l lipofectamin in 36(0.1 serum free medium for 20 minutes at room temperature, then the 
total mixture was mixed with 0.3 ml serum free medium and added to one well. Additional 
0.4 ml of serum free media was added to each well. 4 hours after transfection, cells were 
changed to the regular culture medium. 
Immuno fluorescence Image NIH 3T3, COS7 or PC 12 cells were cultured, 
transfected as described before. Then cells were washed with phosphate buffer saline (PBS, 
pH 7.4) twice and fixed with either 4% paraformaldehyde in PBS at room temperature for 15 
minutes. Then cells were permeablized with 0.2% TritonX-100 on ice for 5 minutes and 
quenched with 50mM NH4CI in PBS for 15 minutes at room temperature. After that, cells 
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were blocked with blocker buffer (1% fat free milk in PBS) for 15 minutes at room 
temperature and then incubated with primary antibody for 1 hour at room temperature. After 
the primary antibody incubation, cells were washed with PBS once and incubated with 
secondary antibody for another 1 hour at room temperature. All the antibodies were diluted 
in the blocker buffer. After the secondary antibody treatment, cells were washed with PBS, 
distilled water, mounted on the glass slide with mountain media (VECTASHELD) and then 
fixed with regular nail polish. Then fixed slides were examined and images were taken by 
either Leica confoucal microscope or Leica fluorescence microscope (Model DIMER2). 
Images were enhanced, deconvolved and/or merged by either the Improvision OpenLab 
software or Adobe Photoshop software. 
Immuno-co-precipitation and Immuno-blot NIH 3T3 cells were cultured in 100mm 
tissue culture disk and transfected with H-Ras Q61L, H-Ras-SDQCE61L and H-Ras-
CDQCE61L cDNAs. 18 hours after transfection, cells were lysed with 1.5 ml lyses buffer 
(150 mM NaCl, 20mM Tris.Cl pH7.5, 20mM MgCl, 0.5% NP-40, 1% protease inhibitor 
cocktail, sigma p-8340). Cell lysates were spun twice at high speed (14000 rpm, 10 minutes) 
at low temperature (4°C) to remove insoluble components. The supernatants were pre-
cleared with lOp.1 protein G agarose beads (Invitrogen) at 4°C for 2 hours with shaking. The 
agarose beads were then removed by low speed centrifuge (lOOOrpm, 4°C, 5 minutes) and 
the supernatants were then incubated with 5j_il antibody cocktail (Ras 238 and 146 
monoclonal antibody mixture, 2:1 ratio) and 15pl new protein G agarose beads at 4°C with 
shaking for over night. After incubation, the unbound proteins were removed by low speed 
centrifuge (lOOOrpm, 4°C, 5 minutes) and the agarose beads were washed 3 times with the 
lyses buffer. Then the beads were mixed 2X SOS-PAGE loading buffer(l% SDS, 20% 
Glycerol, 200mM DTT, 10% 2-mercaptoethanol, 0.04% Bromophenol Blue, 20mM Sodium 
Phosphate pH7.0) and boiled for 10 minutes. After the separation by SOS-PAGE, proteins 
80 
were transferred electrophoretically to polyvinylidene difluoride (PVDF) membrane, and 
non-specific protein binding was blocked by incubating the membrane in casein (Vector 
Laboratories) buffer diluted in TTBS buffer(150mM NaCl, 50mM Tris pH7.4, 0.05% Tween 
20). The membrane was probed with primary antibodies. HRP conjugated secondary 
antibody was used with development by SuperSignal using the manufacturer's protocol 
(PIERCE). 
Soft Agar and Focus Assay 
NIH 3T3 cells or RATI cells were cultured in 60mm tissue culture disk. At -90% 
confluence, cell were transfected with 10, 20, and 30ng DNAs. 10 days after transfection, 
cells were washed with PBS fixed with fix buffer (10% Acetic Acid, 10% Methanol in H2O) 
and stained with 0.5% crystal violet in fix buffer. Cells were then washed with distilled 
water and the number of foci was counted. For the soft agar assay, NIH 3T3 cells were 
transfected with the same amount of H-Ras61L, H-Ras-SDQCE61L and H-Ras-CDQCE61L 
cDNAs. The transfected cells were then cultured in regular culture media containing 0.9% 
agar. 10-14 days after transfection, the number of live cell and live cell form cell clamps 
were counted. The percentage of cells that grow in clamps was then determined by division 
of two numbers. 
Results 
SDQCE and CDQCE mutants are localized on the endomembranes 
Previous study showed a novel H-Ras mutant SDQCE, which lacks the 
palmitoylation site at 181 and has changes in the surrounding charge of that site but retains 
the CaaX motif and is famesylated and palmitoylated, localizes on the endomembranes in 
NIH 3T3 cells [10]. A new similar mutant that restored the potential palmitoylation site of 
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SDQCE at 181, namely CDQCE, was made (Fig. 1 a.). NIH 3T3, COS-1, MDCK and PC 12 
cells were transfected with cDNAs of these two mutants. 18 hours after transfection, 
immuno-fluorescence showed that these two mutants were trapped on the endomembranes 
and absent from the plasma membrane (Fig. 1 b.-e. f.-i.). The predominant location of 
SDQCE was the ER, with some accumulation in a perinuclear site while CDQCE showed 
both ER and substantial Golgi labeling. The 10 C-terminal corresponding amino acid 
residues fused with green fluorescent protein (GFP) chimeras were tested in same manner, 
and similar results were also obtained (data not shown). These data show SDQCE and 
CDQCE mutants are resident of endomembranes and seem unable to get out to the plasma 
membrane. The mechanism for this SDQCE and CDQCE entrapment is conserved in 
different cell types. Since SDQCE protein is famesylated and palmitoylated [10] and 
CDQCE protein is putatively fully lipid modified, they should be able to be transported to 
the plasma membrane. So this entrapment of SDQCE and CDQCE may be the result of 
delayed traffic of these two proteins. To test this possibility, cells were transfected again, but 
were fixed at 48 hours after the transfection to allow the newly synthesized proteins to have 
enough time to be transported to the plasma membrane. However in NIH 3T3 cells (Fig. 1 j. 
k.) and other types of cells (data not shown), there is no sign of plasma membrane location 
of SDQCE and CDQCE proteins or their GFP chimeras (data not shown). This result means 
SDQCE and CDQCE mutants are permanently trapped on the endomembranes. 
SDQCE and CDQCE mutants can bind effector protein and activate downstream 
kinases in vitro 
In the traditional model, the plasma membrane is the major destination and platform 
for Ras proteins targeting and signaling. Moreover, plasma membrane and maybe some 
plasma membrane derived endosomes are though the only place(s) where the Ras signal 
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transduction happens [11]. However this model is challenged by the recent studies from MR 
Philips group. Philips and co-workers showed H- and N-Ras signaling can happen not only 
on the plasma membrane, but also on the ER and Golgi [5-7]. K-Ras4B, though already 
located on the plasma membrane, can even redirect to mitochondrial membranes and signals 
from there to induce cell apoptosis [9]. All these studies revealed a new page for Ras signal 
transduction. However, the physiological meaning of Ras signaling on the endomembranes 
especially on ER membranes still needs to be elucidated, and the difference between 
endomembranes signaling and plasma membrane signaling of Ras protein is still not fully 
understood. The answers of these questions will help people understand better how the same 
signal protein with multiple effectors can generate different biological outcomes by 
compartmentalized signaling. Our SDQCE and CDQCE mutants are very good models for 
studying these issues. In that context, we investigated the signal transduction of SDQCE and 
CDQCE mutants. 
Raf kinase is one of the most important and the best studied Ras effector that induces 
the mitogen-activated protein kinase (MAPK) pathway. To test if SDQCE and CDQCE have 
ability to activate signal transduction, we first checked their ability to bind the Raf kinase. 
We transfected NIH 3T3 cells with the oncogenic form (Q61L) of SDQCE and CDQCE 
cDNAs. After 18 hours, we lysed cells and did immuno-co-precipitation of Raf with Ras to 
see if Raf protein can be co-precipitated with SDQCE and CDQCE Ras. Indeed, the Raf 
kinase is co-precipitated with the active form of the H- Ras SDQCE and CDQCE. These two 
Ras mutants showed though somewhat lower yet still very good efficiency in binding with 
Raf kinase (Fig. 2). This result indicates the carboxyl terminal mutations in SDQCE and 
CDQCE proteins do not affect or have very little effect on the their effector- binding 
domains. This leaves the possibility that SDQCE and CDQCE can activate the 
Raf/MEK/ERK pathway. So we transfect NIH 3T3 cells with oncogenic form (Q61L) 
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cDNAs of SDQCE and CDQCE, after a period expression of protein, we check the cell 
lysates to see if there is any level of increase of phosphorylated ERK. The results showed 
phosphorylated ERK level did increased in the SDQCE61L and CDQCE61L transfected 
cells. These two results strongly suggest that SDQCE and CDQCE can activate the MAPK 
pathway on the endomembranes. Akt (PKB) mediated PI3 kinase pathway is another 
important signaling pathway that is regulated by Ras proteins. Next we examined this 
pathway with same methods. However, both active form of wild type H-Ras and SDQCE or 
CDQCE mutants failed co-immuno-precipitate the PI3K component P85 subunit (data not 
shown). This failure in immuno-co-precipitation may caused by the antibodies we used 
masked the binding domain of Ras for P85. Nevertheless, the downstream kinase, 
phosphorylated Akt level, is increased in these SDQCE61L and CDQCE61L transfected 
cells (Fig. 3). This indicates the PI3 kinase pathway may also be activated by these 
endomembranes trapped H-Ras proteins. 
SDQCE61L and CDQCE61L can bind Raf kinase in vivo 
All the above assays are in vitro assays. It not necessarily means the active form of 
SDQCE and CDQCE mutants can really activate the signal transduction from 
endomembranes in vivo. RBD (Ras Binding Domain) is a domain from Raf kinase that 
exclusively binds the GTP loaded Ras, the active form of Ras. We use GFP-RBD as a probe 
to detect if oncogenic form of SDQCE and CDQCE can indeed activate Raf kinase, and if 
their activation site is really on the endomembranes in vivo. So we co-transfected NIH 3T3 
cells with the GFP-RBD and SDQCE-61L or CDQCE-61L cDNAs and checked if GFP-
RBD can co-localize with these two H-Ras mutants. The results showed both SDQCE-61L 
and CDQCE-61L can bind GFP-RBD well. SDQCE-61L mainly showed activation on the 
ER and nuclear envelope area (Fig. 4 b.) while the CDQCE-61L showed strong 
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between the SDQCE and CDQCE mutants is that the latter may have one more 
palmitoylation, these data suggest that the palmitoylation at H-Ras carboxyl terminus might 
have some effect on its effector-binding domain. However this explanation is least possible 
because palmitoyl lipid is deeply embedded in the lipid bilayer while the Ras effector-
binding domain is in the cytoplasm. A more attractive alternative explanation is that this 
extra palmitoylation can cause a subtle difference of localizations between SDQCE and 
CDQCE on the endomembranes, and this subtle difference of localizations causes a big 
difference on signal transduction. Interestingly, although CDQCE61L had almost the same 
potential in foci forming ability as H-Ras61L, it had very poor competence in making cells 
forming clamps in soft agar (-20% of H-Ras61L), and SDQCE mutants has only half 
competence of CDQCE. This suggests though endomembranes based and plasma membrane 
based H-Ras signal transductions can both activate cell mitogenesis (most possibly through 
the MAPK pathway), the plasma membrane based signaling seems much more powerful 
than the endomembranes based one. Focus assay and soft agar assay reflect two different 
characters of transformed cells. The foci formation depends on the lost of the ability of 
contact inhibition while cell clamp formation in soft agar depends on the continual 
mitogenesis of the cells. Three H-Ras forms, H-Ras61L, SDQCE61L and CDQCE61L, 
localized on different membranes and therefore showed different abilities on generating 
these two transforming characters. This indicates the compartmentalized H-Ras signaling 
may have different preferences for signal transduction pathway. 
SDQCE and CDQCE mutants cause PC 12 cells to show different phenotype 
Another character of oncogenic H-Ras protein was that it can cause PC 12 cells 
differentiation instead of proliferation. So we transfected PC 12 cells with SDQCE61L and 
CDQCE61L cDNAs to see if they could make PC 12 cells generate neurites. One week after 
84 
perinuclear/Golgi area activation (Fig. 4 c.). None of them showed signs of activation on the 
plasma membrane (Fig. 4 b. c.). As a comparison, the activated form of wild type, H-
Ras61L, mainly showed activation on the plasma membrane (Fig. 4 a.). These data indicate 
that CDQCE and SDQCE can bind with Raf kinase when they are GTP loaded, even though 
still on the endomembranes. 
SDQCE and CDQCE mutants show different transforming potentials 
Though we now know the SDQCE and CDQCE can be activated on the 
endomembranes and thus induce the activation of MAPK and PI3K pathways, we still do not 
know what is the difference between this novel endomembranes based signal transduction 
and the classical plasma membrane based signal transduction, i.e. we do not know what is 
the biological outcome difference between these two different signaling modes. One typical 
character of plasma membrane based Ras signal transduction is that when Ras is activated, it 
will activate the MAPK pathway and thus stimulate the cell proliferation. So the oncogenic 
form of Ras protein can cause many types of cells to be transformed. The transformed cells 
are a tumor like cells. They do not have contact inhibition ability; can be suspended in the 
medium and grow without attachment; and can form cell clamps in soft agars. Focus assay 
and soft agar assay are two typical assays for detecting if cells are transformed. We did both 
assays (see material and methods) for SDQCE61L and CDQCE61L mutants to see if their 
endomembranes based signal transduction has same transforming potential as normal Ras 
signal transduction. To our surprise, in the focus assay, CDQCE61L and SDQCE61L 
exhibited very different competence. CDQCE61L showed equivalent (-80% in RATI cells, 
Fig. 5 b.) or even more (-130% in 3T3 cells, Fig. 5 a.) transforming potential comparing to 
H-Ras61L, while SDQCE61L, although also localized on the endomembranes, showed only 
about 20-30% potential of H-Ras61L ( Fig. 5 a. b.). Since the only structural difference 
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the transfection, SDQCE61L and CDQCE61L still localized on the endomembranes and 
they did induce neurite growth in some cells (Fig. 6 a. b. c.). However only very few portion 
(<1%) SDQCE61L and CDQCE61L transfected PC12 cells can generate neurite. Most of 
SDQCE61L transfected cells have only very short neurites (Fig. 6 d.) Many CDQCE61L 
transfected cells also have very short neurites similar to the SDQCE61L transfected cells. 
However, more importantly, some CDQCE61L transfected cells generated a veiy novel 
phenotype that cannot be observed in either H-Ras61L or SDQCE61L transfected cells. In 
this novel phenotype, the transfected cells produced a unique incomplete differentiation in 
which an actin-rich ruffle encircled the cell without producing filopodia or extension (Fig. 6 
e. f.). These results again confirmed that the subtle difference between SDQCE and CDQCE 
in membrane locations will make them signal differently. These data also showed there are a 
lot of difference between endomembranes based signal transduction and plasma membrane 
based signal transduction for H-Ras. 
Discussions 
Two H-Ras mutants SDQCE and CDQCE are found entrapped permanently on the 
endomembranes. SDQCE is proved famesyled and palmitoylated [10] and CDQCE is 
putatively fully lipid modified. However the lipid modifications do not bring them the ability 
to traffic to the plasma membrane. The previous studies showed these post-translational lipid 
modification is indispensable for Ras proteins to be transported to the plasma membrane [10, 
12-15], and may be the mechanism for H- and N- Ras being transported via vesicular 
pathway [4, 12]. That SDQCE and CDQCE neither show on the plasma membrane nor on 
the transporting vesicles indicates the mechanism for H- and N-Ras vesicular transportation 
may not be just as simple as lipid modification. The mechanism cause SDQCE and CDQCE 
trapped on endomembranes seem conserved in many cell types. It is interesting to know the 
87 
details why they are trapped since the answer may reveal a lot of information on the 
mechanism widely used for isoprenylated proteins transportation. Some studies (H. Zheng 
and JE. Buss unpublished results) show H-Ras may use a non-vesicular pathway to target to 
plasma membrane. Maybe it is the machinery used for that non-vesicular pathway cause 
SDQCE and CDQCE being trapped on the endomembranes since they cannot get to the 
plasma membrane either by that non-vesicular pathway. 
Although on endomembranes, SDQCE and CDQCE do not lost their abilities to bind 
effector protein. Comparing with normal H-Ras, the efficiency of this binding seems reduced. 
Nevertheless, the oncogenic form of SDQCE and CDQCE can still successfully activate 
their downstream effectors. The results from focus assay and soft agar assay suggest the 
endomembranes based signal transduction prefers some specific pathway. The physiological 
meaning of Ras proteins signaling on endomembranes especially on ER still needs to be 
illuminated. However, a lot of portion of H- and N- Ras protein have been shown on the 
Golgi and ER at steady state [4, 12]. Moreover about one third of human cancers contain 
mutations in Ras genes [16]. How these mutated Ras proteins signal on endomembranes in 
tumor cells become pathological meaningful. 
The localization of SDQCE and CDQCE are quite similar. There is a subtle 
difference in their membrane distribution. The SDQCE predominantly localize on the ER 
membrane, with some accumulation in a perinuclear area while CDQCE showed both ER 
and substantial Golgi labeling. However the biological outcomes that generated by these two 
proteins' signal transduction are very different. CDQCE transformed cells lost a lot of their 
ability of contact inhibition whereas SDQCE transformed cells seem not affected very much. 
CDQCE mutant can also induce an incomplete differentiation in PC 12 cells yet SDQCE is 
incapable. Moreover, both SDQCE and CDQCE signaling are different from the wild type 
H-Ras signal transduction. These results indicate even same protein, when localized on 
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different membranes, would induce very different signal events and thus change the final 
effect on the cell. 
References 
1. Hancock, J.F., Ras proteins: différents signals fromdifferent locations. Nature, 2003. 
4: p. 373-384. 
2. Dai, Q., et al., Mammalian prenylcysteine carboxyl methyltransferase is in the 
endoplasmic reticulum. J. Biol. Chem., 1998. 273: p. 15030-15034. 
3. Schmidt, W.K., Tarn, A., Fujimura-Kamada, K., and Michaelis, S., Endoplasmic 
reticulum membrane localization of Rcelp and Ste24p, yeast proteases involved in 
carboxyl-terminal CAAXprotein processing and amino-terminal a-factor cleavage. 
Proceedings of the National Academy of Science, USA, 1998. 95: p. 11175-11180. 
4. Apolloni, A., et al., H-ras but not K-ras traffics to the plasma membrane through the 
exocyticpathway. Mol. Cell. Biol., 2000. 20: p. 2475-2487. 
5. Bivona, T.G., et al., Phospholipase Cyactivates Ras on the Golgi apparatus by 
means ofRasGRPl. Nature, 2003. 424: p. 694-698. 
6. Chiu, V.K., et al., Ras signalling on the endoplasmic reticulum and the Golgi. Nature 
Cell Biology, 2002. 4: p. 343-350. 
7. Castro, I.P.d., et al., Ras Activation in Jurkat T cells following Low-Grade 
Stimulation of the T-Cell Receptor Is Specific to N-Ras and Occurs Only on the 
Golgi Apparatus. Molecular and Cellular Biology, 2004: p. 3485-3496. 
8. Augsten M, P.R., Biskup C, Rennert K, Wittig U, Beyer K, Blume A, Wetzker R, 
Friedrich K, Rubio I, Live-cell imaging of endogenous Ras-GTP illustrates 
predominant Ras activation at the plasma membrane. EMBO, 2006. 7(1): p. 46-51. 
89 
9. Trever G. Bivona, S.E.Q., Brian O. Bodemann, Ian M. Ahearn, Michael J. Soskis, 
Adam Mor, John Miura, Heidi H. Wiener, Latasha Wright, Shahryar G. Saba, Duke 
Yim, Adam Fein, Ignacio P HE ez de Castro, Chi Li, Craig B. Thompson, Adrienne D. 
Cox and Mark R. Philips, PKC Regulates a Farnesyl-Electrostatic Switch on K-Ras 
that Promotes its Association with Bcl-Xl on Mitochondria and Induces Apoptosis. 
Molecular Cell, 2006. 21(4): p. 481-493. 
10. Willumsen, B.M., et al., Move/ determinants of H-Ras plasma membrane localization 
and transformation. Oncogene, 1996. 13: p. 1901-1909. 
11. Vieira AV, L.C., Schmid SL., Control of EGF receptor signaling by clathrin-
mediated endocytosis. Science., 1996. 274(5295): p. 2086-9. 
12. Choy, E., et al., E ndomembrane trafficking of Ras: the CaaX motif targets proteins to 
the ER and Golgi. Cell, 1999. 98: p. 69-80. 
13. Hancock, J.F., H. Paterson, and C.J. Marshall, A polybasic domain or palmitoylation 
is required in addition to the CAAX motif to localize p21ras to the plasma membrane. 
Cell, 1990. 63: p. 133-139. 
14. Hancock, J.F., et al., A CAAX or a CAAL motif and a second signal are sufficient for 
plasma membrane targeting of ras proteins. EMBO J., 1991. 10: p. 4033-4039. 
15. Schroeder, H., et al., S-acylation and plasma membrane targeting of the famesylated 
carboxy-terminal peptide ofN-ras in mammalian fibroblasts. Biochemistry, 1997. 30: 
p. 13102-13109. 
16. Lowy, DR. and B.M. Willumsen, function and regulation of Ras. Ann. Rev. 
Biochem., 1993. 62: p. 851-891. 
90 
Figure Legends 
Figure 1 a. Structure of SDQCE and CDQCE mutants. 
Figure 1 b.-e. NIH 3T3, COS-1, MDCK and PC 12 cells were transfected with H-Ras 
SDQCE cDNA. 18 hours after transfection, cells were fixed, immuno-stained and examined 
by the fluorescent microscope. Arrowheads show location of the H-Ras SDQCE proteins. 
Figure 1 f.-i. NIH 3T3, COS-1, MDCK and PC 12 cells were transfected with H-Ras 
CDQCE cDNA. 18 hours after transfection, cells were fixed, stained and examined by the 
fluorescent microscope. Arrowheads show location of the H-Ras CDQCE proteins. 
Figure 1 j. and k. SDQCE and CEDCE are permanently localized on the endomembranes. 
NIH 3T3 cells were transfected with H-Ras SDQCE and CDQCE cDNAs. 48 hours after 
transfection, cells were fixed and examined by the fluorescent microscope. Arrowheads 
show location of the H-Ras SDQCE and CDQCE proteins. 
Figure 2 a. Raf kinase can be co-immuno-precipitated with active form of SDQCE and 
CDQCE mutants. NIH 3T3 cells were transfected with H-Ras-Q61L-SDQCE and H-Ras-
Q61L-CDQCE cDNAs. 18 hours after transfection, cell lysates were immuno-precipitated 
with anti-H-Ras anti bodies. The immuno-precipitations were separated by SDS-PAGE and 
were electro-transferred to a PVDF membrane. The PVDF membrane were then immuno-
blotted with anti-Ras and anti-Raf antibodies. 
Figure 2 b. SDQCE-61L and CDQCE-61L mutants can increase the phosphorylated ERK 
levels in NIH 3T3 cells. NIH 3T3 cells were transfected with H-Ras-Q61 L-SDQCE and H-
Ras-Q61L-CDQCE cDNAs. 18 hours after transfection, cell lysates were separated by SDS-
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PAGE and were electro-transferred to PVDF membranes. The PVDF membranes were then 
immuno-blotted with anti-ERK and anti-Pi-ERK antibodies. 
Figure 3 SDQCE-61L and CDQCE-61L mutants can increase the phosphorylated Akt levels 
in NIH 3T3 cells. NIH 3T3 cells were transfected with H-Ras-Q61 L-SDQCE and H-Ras-
Q61L-CDQCE cDNAs. 18 hours after transfection, cell lysates were separated by SDS-
PAGE and were electro-transferred to PVDF membranes. The PVDF membranes were then 
immuno-blotted with anti-Akt and anti-Pi-Akt antibodies. 
Figure 4 a. b. c. SDQCE-61L and CDQCE-61L mutants can activate from endomembranes 
in NIH 3T3 cells. NIH 3T3 cells were co-transfected with GFP-RBD and H-Ras61L or H-
Ras-SDQCE61L or H-Ras-CDQCE61L cDNAs. 18 hours after transfection, cells were fixed 
and stained for image. Arrowheads show the co-localization of GFP-RBD and Ras proteins. 
Figure 5 a. b. SDQCE-61L and CDQCE-61L mutants showed different potentials in foci 
formation. NIH 3T3 cells (a.) or RATI cells (b.) were transfected with H-Ras61L or H-Ras-
SDQCE61L or H-Ras-CDQCE61L cDNAs. 14 days after transfection, cells were fixed and 
stained for counting. 
Figure 5 c. SDQCE-61L and CDQCE-61L mutants have poor ability in cell clamp 
formation in soft agar. Same numbers of cells from H-Ras61L or H-Ras-SDQCE61L or H-
Ras-CDQCE61L NIH 3T3 stable cell lines were seeded in the soft agar medium. 7 days a 
after seeding, cell clamps growing in the soft agar were counted. 
Figure 6 a. b. c. SDQCE-61L and CDQCE-61L mutants can induce less than 1% neurite 
outgrowth in PC 12 cells. PC cells were transfected with H-Ras61L or H-Ras-SDQCE61L or 
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H-Ras-CDQCE61L cDNAs. 7 days after transfection, cells were fixed and stained for image. 
Arrowheads show the localization of Ras proteins. 
Figure 6 d. Over 70% SDQCE-61L and CDQCE-61L transfected PC12 cells have only very 
short neurites. PC cells were transfected with H-Ras-SDQCE61L or H-Ras-CDQCE61L 
cDNAs. 7 days after transfection, cells were fixed and stained for image. Arrowheads show 
the localization of Ras proteins and actin. 
Figure 6 e. f. About 30% CDQCE-61L transfected PC12 cells produced a unique 
incomplete differentiation. PC cells were transfected with H-Ras-CDQCE61L cDNAs. 7 
days after transfection, cells were fixed and stained for image. Arrowheads show the 
localization of Ras proteins and actin. 
93 
Figure 1 a. 
WT 
S s s 
—CMSCKC-oMe 
CDQCE 
SDQCE 
s s s 
—CDGCI-C-oMo 
5 S 
94 
Figure 1 b. 
> * 
SDQCE in NIH 3T3 cells 
Figure 1 c. 
SDQCE in COS-1 cells 
95 
Figure 1 d. 
SDQCE in MDCK cells 
Figure 1 e. 
% : 
SDQCE in PC 12 cells 
96 
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Figure 1 h. 
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Figure 1 j. 
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Figure 4 a. 
H-Ras61L with GFP-RBD 
Figure 4 b. 
H-Ras-CDQCE-61L with GFP-RBD 
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Figure 4 c. 
H-Ras-SDQCE61L with GFP-RBD 
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Figure 6 a. 
H-Ras61L transfected PC 12 cell 
Figure 6 b. 
CDQCE61L transfected PC 12 cell 
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Figure 6 c. 
SDQCE61 transfected PC 12 cell 
Figure 6 d. 
SDQCE61L transfected PC 12 cells 
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Figure 6 e. 
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Figure 6 f. 
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Chapter 4: Determination of the Micro-localization of H-Ras on the 
Plasma Membrane 
Some results have been published in Journal of Biological Chemistry 
Hui Zheng, and Janice E. Buss 
Department of Biochemistry, Biophysics and Molecular Biology 
Iowa State University, Ames Iowa 50011 
Contributions to the paper "Distinct Rates of Palmitate Turnover on Membrane-
bound Cellular and Oncogenic H-Ras" that has been published in in Journal of 
Biological Chemistry 
My major contribution to this paper is determining the micro-localization of H-Ras 
on the cells. Since we want to examine if the difference between palmitate turnover rate of 
oncogenic and cellular form of H-Ras is due to the lipid raft domain shelter, we need check 
whether there is a difference of membrane micro-localization between these two forms of H-
Ras. To do this, I first checked the membrane micro-localizations of oncogenic and cellular 
form of H-Ras in detergent untreated cells. Since H-Ras protein binds to the inner leaflet of 
plasma membrane, to visualize H-Ras by immuno-fluorescence required permeablization of 
cell membrane. All the traditional methods for cell permeablization will destroy the lipid raft 
microdomains. I adopted a sonication based method to check detergent untouched membrane 
and found the localizations of both oncogenic and cellular form of H-Ras are distinct from 
caveolae, a special type of lipid raft. Because caveolae is not the only kind of lipid raft on the 
plasma membranes, I used a gradient centrifugation based method to check if any form of H-
Ras is associated with other types of raft membranes. The old method for raft membrane 
segregation requires sodium carbonate buffer treatment, which has a very high pH will 
potentially destroy the intrinsic membrane binding property of Ras proteins. I improved this 
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method by combining sonication and detergent treatment. In the improved method, the risk 
of losing the Ras intrinsic membrane binding property is decreased. With this improved 
method I found both oncogenic and cellular forms of H-Ras are in detergent sensitive 
membrane fractions, i.e. a non-raft domains. The results of my contributions are represented 
in Figure 5 and Figure 6. 
Introduction 
The lipid raft is a new hypotheses that has been developed during recent years to 
more accurately describe the structure of biological membranes [1-4]. In this model, a 
dynamic microdomain (lipid raft) within the lipid bilayer is proposed. This proposed 
microdomain is mainly composed of cholesterol and sphingolipids and maybe some kind of 
phospholipids. The mechanism for this microdomain formation is that the long straight 
saturated lipids of the side chains of the sphingolipids make it easy for sphingolipids to form 
a tight interaction among each other and cholesterols and thus form a liquid-ordered state 
microdomain. Some phospholipids with saturated side chains may also join this 
microdomain. Outside of this microdomain, is the sea formed by the majority of 
phospholipids. Since the side chains of phospholipids have more unsaturated kinked lipids, 
which prevent them from tightly packing, this phospholipids sea is more fluid than the lipid 
raft [5]. In the early literature, detergent resistant membrane (DRM) is often used to describe 
this microdomain or lipid raft because the structural feature makes the lipid rafts more 
detergent resistant than the other (liquid-disordered) part of the membrane. Because the 
putative size of these microdomains is ~50nm in diameter [6], a size that cannot be 
visualized by light microscopy, to prove the existence of the lipid raft in live cells is very 
difficult. So the concept of lipid raft is still a controversial issue [7]. 
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The most important reason for people showing particular interest in lipid raft is that it 
can harbor discrete sets of proteins that differ from those found in the bulk membrane. Many 
proteins such as glycosylphosphatidyllinositol(GPI)-anchored proteins [8, 9], palmitoylated 
proteins such as Hedgehog [10], double acylated proteins like Src-family kinases [7], a-
subunit of the heterotrimeric G-protein [11] and some transmembrane proteins [12] are 
known have high affinity for the lipid raft. This specialized protein recruitment feature gives 
lipid rafts an important role in the signal transduction. Many studies showed a lot of signal 
transduction events are particularly favored to happen inside the lipid rafts. These signal 
transduction events include immunoglobulin E signaling [13],T-cell antigen receptor 
signaling [14], B-cell receptor signaling [15], insulin receptor signaling [16], eNOS and 
Hedgehog signaling [17] etc. 
H-Ras are palmitoylated and therefore likely partition into the lipid raft domain. 
However, there are several other properties that make this model too simplistic. The farnesyl 
group at the C-terminal end of the Ras protein is not accommodated well in an ordered 
domain and provides a repulsive force for Ras partitioning into the lipid raft. Moreover the 
linker part (166-180) in the adjacent, C-terminal hypervariable region provides an additional 
attraction to cholesterol-independent (non-raft) membrane domain [18]. Previous studies 
showed a lot of signal transductions involves effector proteins clustering into a lipid raft 
domain [13, 14, 15]. However it is still unknown if this is true in Ras regulated signal 
transduction. So it is interesting issue to know if the activation can influence the 
participation of H-Ras into the raft domain. Ras proteins has multiple effectors, how does 
Ras protein selective bind different effector upon different stimulation is a very interesting 
issue. One possible explanation is different receptors and corresponding Ras effectors have 
different preference to non-raft or raft-microdomains and by selective participating into 
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different microdomains Ras can choose a preferred pathway to activate. Based on above 
hypotheses, we studied micro-localizations of H-Ras on the plasma membranes. Results 
showed when at activated state, H-Ras is predominantly in the non-raft domains while the 
inactivated form of H-Ras showed slightly higher affinity than the activated one. Both active 
and inactive forms of H-Ras seem not in caveole, a specialized lipid raft. 
Material and Methods 
Cell Culture NIH 3T3 cells stably transfected with H-Ras61L, H-Ras 12R, 59T (B. 
Willumsen, University of Copenhagen), c-H-Ras (L. Quilliam, Indiana University School of 
Medicine), and inducible H-Ras 17N (A. Kazlauskas, Harvard Medical School) were grown 
at 10% CO2 in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% 
calf serum (Hyclone). 
Preparation of Subcellular Fractions For preparation of soluble and crude 
membrane-containing fractions, NIH 3T3 cells were lysed in hypotonic buffer (1 mM Tris, 
pH 7.4, 1 mM MgCl2,0.1% aprotinin (Calbiochem). with 1 mM Pefabloc, 1 ng/ml leupeptin, 
1 |iM pepstatin (Roche Diagnostics)) by Bounce homogenization. The ionic strength was 
adjusted to 0.15 M NaCl, and the sample was subjected to centrifugation at 100,000 xg for 
30 min. Proteins in the cytosolic fraction (SI00) were precipitated with 4 volumes of ice-
cold acetone. Equal portions of both the precipitated soluble proteins and particulate fraction 
(PI 00) were solubilized in electrophoresis sample buffer, separated by SDS-PAGE on 12.5% 
gels, transferred to a polyvinylidene difluoride membrane, and selected proteins were 
detected by immunoblotting. 
Density Gradients Completely detergent-free density gradients were based on previous 
protocols [19, 20], with the following major steps: cells were lysed in the hypotonic buffer as 
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above by passage through a 26-gauge needle, nuclei were removed by low speed 
centrifugation, then cytosol was removed, and crude membranes were collected by 
sedimentation at 100,000 x g for 30 min. The PI00 pellet was resuspended in gradient buffer 
(50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM dithiothreitol, 10% sucrose, 1% protease 
inhibitor mixture (Sigma number P-8340)) and homogenized by passage 15 times through a 
26-gauge needle. The homogenized sample was further subjected to five rounds of sonication 
at 15 watt output (model VC 130, Sonics & Materials, Inc.), each consisting of five 1-s 
pulses with a 30-s cooling break with both sample and probe in ice. A portion of the 
sonicated sample (300 ^1) was mixed with 2 volumes of 60% Optiprep (Sigma number D-
1556) to produce a 40% Optiprep concentration, then overlain with a total of 4.2 ml of 
decreasing concentrations from 37.5 to 20% of Optiprep diluted with gradient buffer. The 
gradient was then subjected to centrifugation at 30,000 rpm (Beckman SW55 rotor), 4 °C 
over 16 h. Fractions (600 |il) were collected from the top of the tube, concentrated by 
trichloroacetic acid precipitation, subjected to SDS-PAGE, and probed with H-Ras, 
transferrin receptor or caveolin antibodies by immunoblotting. To examine the proteins 
separated by the neutral, detergent-free gradient, the entire fraction was precipitated with 
trichloroacetic acid, separated by SDS-PAGE, and detected by staining with Coomassie 
Blue. 
Similar neutral pH Optiprep gradients were also used for samples pretreated with 0.15 M 
sodium carbonate buffer [21]. Pretreatment consisted of incubating the samples at pH 11 for 
10 min on ice, sonication as above, then immediate neutralization by addition of 1/3 volume 
of 0.5 M MES buffer (pH 5.0), and confirming that the solution had been adjusted to pH 7.5. 
Detergent-treated samples were prepared starting from the PI00 as above, but pretreatment 
consisted of resuspending the PI00 in gradient buffer containing 1 or 0.1% Triton X-100, on 
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ice, for 30 min. Gradients were prepared as above, with Triton-treated samples were overlain 
with Optiprep gradient buffer, without Triton [22, 23]. 
Immunoblotting Proteins collected by trichloroacetic acid or acetone precipitation were 
resuspended in electrophoresis sample buffer. After separation by SDS-PAGE, proteins were 
transferred to polyvinylidene difluoride membranes and nonspecific protein binding was 
blocked by incubating the membrane in 1.25% nonfat dry milk in Tris-buffered saline 
overnight. Membranes were probed with the H-Ras-specific mouse monoclonal antibody, 
146-3E4 (Quality Biotech), a rabbit antibody to caveolin-1 (CI3630, Transduction 
Laboratories), or mouse antibody to the transferrin receptor (Zymed Labs). For density 
gradient samples, horseradish peroxidase-labeled secondary antibodies (anti-mouse or anti-
rabbit, Pierce) were used with detection by chemiluminescence (Pierce 34080). 
Sonication and Immunofluorescence of Membrane Fragments NIH 3T3 cells were 
plated in 12-well culture cassettes on glass coverslips (18 mm) coated with 100 ng/ml poly-
L-lysine (Sigma) and 50 fxg/ml fibronectin (Sigma). Two days later the cells were processed, 
on ice, as described [24, 25], in a sonication buffer that contained GDP/MgClz with the 
sonication probe placed 12 mm above the coverslip and sonicated for a 1-s burst at 4 watts 
using the Sonics Vibra Cell ultrasonic processor and washed in ice-cold sonication buffer. 
Samples were fixed with fresh 4% formaldehyde on ice and quenched with 50 mM 
ammonium chloride, then incubated with blocking buffer (2% horse serum and 0.4% bovine 
serum albumin in phosphate-buffered saline). Sonicated cells were incubated for 1 h at room 
temperature with anti-H-Ras (Y13-238, 1:500 dilution, 0.5 ng/ml) and anti-caveolin 
(CI3630, 1:400 dilution, 0.625 ng/ml, Transduction Laboratories) diluted in the blocking 
buffer. Secondary antibodies (Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 594 
goat anti-rabbit IgG from Molecular Probes) were diluted 1:700 in blocking buffer, to 2.8 
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Hg/ml. The slips were mounted in Vectashield mounting medium (Vector Laboratories) and 
photographed using a xlOO oil immersion lens on a Nikon Eclipse E800 microscope with 
Spot RT digital camera (Roche Diagnostics). Images were captured in color, imported into 
and overlaid using Adobe Photoshop. The alignment control was incubated as above using 
the polyclonal anti-caveolin and both a green Alexa Fluor 488 goat anti-rabbit serum and red 
Alexa Fluor 594 goat anti-rabbit serum and showed 100% alignment (data not shown). 
Results 
H-RasWT does not co-align with caveolin in native membranes 
Caveolae is the first lipid raft that was identified by their unique flask-shape 
morphology [26, 27]. The formation of caveolae is depend on a cholesterol tightly binding 
palmitoylated hairpin-shaped protein caveolin. Although there have been reports that H-Ras 
can be found within caveolae in baby hamster kidney cells or Madin-Darby canine kidney, 
using immunogold electron microscopy [28, 29], we wished to observe the distribution of 
caveolin and cellular and oncogenic H-Ras proteins in NIH 3T3 fibroblast cells on a larger 
scale, yet without permeabilizing the membranes with solvents or detergents. For this we 
adopted a technique used previously to study the localization of G protein subunits and the 
related GTPase, TC10, in which sonication of cells grown on coverslips is used to remove 
the overlying cell body and reveal the basal plasma membrane [23, 25, 30-33], The adherent 
plasma membrane is then fixed with formaldehyde and proteins are detected in situ without 
exposing the membrane fragments to detergent. This procedure for observation of proteins in 
native membranes showed caveolin staining as small dots, presumably representing its 
location in caveolae on the basal surface of the NIH 3T3 fibroblasts (Fig. 1 a.). H-Ras WT 
was also present as numerous small dots on the basal plasma membrane (Fig. 1 a.). 
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However, when observed at higher magnification, there was very little overlap between the 
dots of H-Ras WT and those of caveolin (Fig. 1 a.), although both proteins were intimately 
intermingled. For caveolin, some of the dots aligned with H-Ras WT dots and appeared 
yellow in the merged image. However, many caveolin puncta had no apparent association 
with any H-Ras WT structure and remained red. More importantly, there were more spots of 
H-Ras WT, so most of the green H-Ras WT dots had no caveolin counterparts. Likewise, on 
membranes prepared from cells transformed by H-Ras61L, only a small portion of overlap 
between the oncogenic H-Ras and caveolin was observed, and most of the H-Ras61L was 
outside of the caveolin-containing puncta (Fig. 1 b.). Although caveolae are found as a 
platform in some signal transductions [34], some cell types such as lymphocytes can still 
signal without caveolae since they do not express caveolin at all. The data shown above 
indicate in NIH 3T3 cells, H-Ras regulated signal transduction seem not dependent largely 
on the caveolae. 
Equivalent distribution of oncogenic and cellular H-Ras in membrane domains 
Several studies have now suggested that H-Ras proteins may partition into lipid raft 
microdomains [28, 35, 36]. Although only a small amount of H-Ras WT and H-Ras61L 
appeared to reside directly within the caveolar subset of rafts, the distributions of cellular and 
oncogenic forms of H-Ras were further compared using multiple biochemical fractionation 
techniques. One prevalent method of raft membrane preparation exposes membranes to 0.15 
M (occasionally even 0.5 M) sodium carbonate (pH 11), followed by sonication to disrupt 
cytoskeletal attachments to membrane fragments [28, 37, 38]. This technique is risky for H-
Ras proteins, as the thioester bonds between the palmitates and protein are susceptible to 
high pH buffer, and quite substantial amounts of MES buffer must be used to thoroughly 
neutralize the carbonate. As has been noted by others [39], for K-Ras4B proteins, which rely 
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upon a highly basic, lysine-rich domain for attachment to membranes, pH 11 will neutralize 
the positive charge of the lysine and potentially allow release or new, inappropriate 
partitioning of the protein. Using this non-detergent method, with immediate, careful 
neutralization of the carbonate and thorough sonication (see "Experimental Procedures"), 
caveolin-containing membranes could be separated, as expected, in the top fractions of the 
gradient (Fig. 2 a.). As seen previously [20, 28, 40], the H-Ras WT protein was also present 
in these fractions (Fig. 2 a.). Similarly, the H-Ras61L protein was found primarily in 
buoyant membranes (Fig. 2 a.). 
In light of the concerns noted above, a neutral pH, completely detergent-free gradient 
separation has also been adopted in some studies [19, 41]. Because cytoskeletal structures 
are known to differ between normal and transformed cells, multiple, brief rounds of 
sonication [21] were used to ensure complete disruption of cytoskeletal structures that might 
ensnare H-Ras and prevent its flotation. After removal of the much more abundant cytosolic 
proteins, a profile of the crude PI 00 membrane proteins distributed in the different fractions 
showed that a veiy abundant, ~44-kDa protein (presumably actin) remained largely at the 
bottom of the gradient (Fig. 2 b.). Although early models envisioned that what would now be 
called rafts might occupy only 10% of the membrane, the results here are in line with studies 
that now estimate raft-like microdomains may cover over one-third of the cell surface [42, 
43]. In these neutral gradients, H-Ras WT was again found in membranes at the top of the 
gradient, as was caveolin (Fig. 2 c.). In addition, essentially all of H-Ras61L was present on 
membranes in the upper fractions of the gradient (Fig. 2 c.). These results from both 
carbonate and neutral pH gradients agree with those reported recently for cellular and H-
RasV12 [41], 
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A second method for examining association of a protein with membrane subdomains 
takes advantage of the tight lipid packing in these regions, which causes the domains to resist 
dissolution in cold, non-ionic detergents, and allows their separation as detergent-resistant 
membranes (DRMs). In membranes exposed to a standard, ice-cold 1% Triton X-100 
extraction protocol, we found, as have others [22, 44, 45], that H-Ras, whether cellular or 
oncogenic (Fig. 2 d.), was absent from DRMs. The 1% Triton X-100 also extracted some of 
the caveolin (Fig. 2 d.). 
Other laboratories have found that some proteins, most notably the T cell receptor 
and the FcsRl receptor of mast cells, are released by exposure to 1% Triton X-100, but can 
be successfully isolated with DRMs if the amount of Triton X-100 is decreased to less than 
0.2% [14, 46]. To examine if H-Ras proteins were also in this category, samples were pre-
treated with only 0.1% Triton X-100 and membranes were separated on detergent-free 
gradients. In these gradients, caveolin-containing DRMs floated to the top of the density 
gradient (Fig. 2 d.). Transferrin receptor, a marker for non-raft, detergent-sensitive domains, 
was found in the bottom fractions of the gradient, as expected. However, H-Ras WT and H-
Ras61L (Fig. 2 d.) were again separated from the DRMs. This indicated that in NIH 3T3 cell 
membranes the interactions of both types of H-Ras were sensitive to even low amounts of 
Triton X-100. 
Thus, on four types of density gradients, the properties of membranes containing cellular or 
oncogenic H-Ras were indistinguishable. In the absence of detergent, both proteins appeared 
to reside almost completely in buoyant membranes of a density similar to that of caveolae. If 
samples were exposed to Triton X-100, both cellular and oncogenic proteins were separated 
from these membrane subdomains. 
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Discussions 
The various gradient separations used here and in the literature are subject to 
conflicting interpretations. Non-detergent methods have no intrinsic features that should 
discriminate the density of raft and non-raft domains from plasma membranes. They also rely 
on thorough and reproducible sonication to disrupt cytoskeletal structures that will vary with 
cell type. Detergent-based methods must rigorously maintain consistent ratios of detergent to 
cellular lipids. Using the detergent-based approach, there are compelling studies that indicate 
prenylated proteins in general, and H-Ras specifically, are not in raft-like membranes [22, 
47]. However, there are also reports that the biophysical "impairment" of an isoprenoid does 
not exclude active Ras proteins from raft-like membranes in living cells [48]. At an even 
more fundamental level, there still are no guidelines to distinguish a protein that is loosely 
raft-embedded and easily dislodged by detergent, from a protein in a disordered membrane 
that becomes dissolved by the detergent. The important conclusion for H-Ras is that we and 
others find cellular and oncogenic forms in locations that are indistinguishable, and there is 
no sign that effector proteins will encounter oncogenic H-Ras proteins in a more exposed 
position, or cellular H-Ras in a more protected site. 
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Figure legends 
Figurel a. and b. H-Ras WT and H-Ras61L do not co-align with caveolin. NIH 3T3 
cells were transfected with H-Ras WT and H-Ras61L cDNAs. 24 hours after transfection, 
cells were sonicated. After sonication, membrane pieces were fixed and immuno-stained 
with both H-Ras antibody and caveolin antibody, then imaged. Arrowheads show the 
localizations of H-Ras and caveolin. 
Figure 2 a. H-Ras WT and H-Ras61L are in low-density membranes after carbonate based 
gradient centrifugation. NIH 3T3 cells were transfected with H-Ras WT and H-Ras61L 
cDNAs. 24 hours after transfection, cells were lysed and fractioned. The PI00 samples were 
sonicated, treated with 0.15 M sodium carbonate for 30 min, then immediately neutralized 
and separated on neutral, carbonate-free gradients. Fractions were collected from the top, 
concentrated by trichloroacetic acid precipitation, and separated by SDS-PAGE. H-Ras 
proteins or caveolin were detected by immunoblotting. 
Figure 2 b. The profile of proteins present in fractions pooled from three detergent-free 
neutral gradients. NIH 3T3 cells were transfected with H-Ras WT and H-Ras61L cDNAs. 24 
hours after transfection, cells were lysed and fractioned. The PI00 samples were sonicated in 
neutral buffer and separated on neutral Optiprep gradients. Samples from different gradient 
fractions were collected, concentrated with acetone, separated by SDS-PAGE and stained 
with Coomassie Blue. The positions of molecular weight standards are shown. The abundant 
44-kDa protein in the bottom fractions (presumably the cytoskeletal protein actin) is 
indicated with an arrow. 
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Figure 2 c. H-Ras WT and H-Ras61L are in same low-density membranes fractions as 
caveolin after neutral detergent free gradient centrifugation. NIH 3T3 cells were transfected 
with H-Ras WT and H-Ras61L cDNAs. 24 hours after transfection, cells were lysed and 
fractioned. The PI 00 samples were sonicated in neutral buffer and separated on neutral 
Optiprep gradients. Samples from different gradient fractions were collected, concentrated 
with trichloroacetic acid, separated by SDS-PAGE. H-Ras proteins or caveolin were detected 
by immunoblotting. 
Figure 2 d. H-Ras WT and H-Ras61L are in soluble membranes fractions after TritonX-
100 treated gradient centrifugation. NIH 3T3 cells were transfected with H-Ras WT and H-
Ras61L cDNAs. 24 hours after transfection, cells were lysed and fractioned. The PI00 
samples were sonicated in neutral buffer and treated with either 1% or 0.1% TritonX-100 on 
ice for 30 minutes. Then were separated on neutral detergent free Optiprep gradients. 
Samples from different gradient fractions were collected, concentrated with trichloroacetic 
acid, separated by SDS-PAGE. H-Ras proteins or caveolin were detected by immunoblotting. 
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Chapter 5 General Conclusions 
Summary of Our Studies 
The work presented in this dissertation describes how the carboxyl terminal lipid 
modifications affect the transportation, signal transduction and micro-localizations of H-Ras 
protein. The already known traffic pathway for H-Ras to the plasma membrane is Golgi 
mediated classical vesicular transportation [1]. However, we found the H-Ras transportation 
has many different features other than the classical pathway, and thereby discovered a new 
pathway for H-Ras targeting to the plasma membrane. We also found two H-Ras mutants 
that are permanently trapped on the endomembranes. By comparing them with the wild type 
H-Ras, we demonstrated that although these two mutants have similar effector interactions 
they show distinct biological activities. Finally we studied the micro-localizations of H-Ras 
protein on the plasma membrane and found the predominant microdomains for H-Ras 
localization are non-lipid raft microdomains, and this localization is independent of the 
activation status of H-Ras. 
The first work we did is in chapter 2 that is mainly focus on the traffic of H-Ras. 
Initial experiment for characterizing H-Ras transportation issue is comparing it with YFP-
GT46, a protein typically uses the classical vesicular transportation pathway for plasma 
membrane targeting. We found a lot of differences between two these two proteins' traffic. 
First we found H-Ras does not co-localize with YFP-GT46 in the Golgi/perinuclear area in 
many cells. Second, we discovered the transportation of H-Ras to the plasma membrane is 
much faster than that of YFP-GT46. Finally we found when the COPI or COPII coated 
vesicular transport from ER to Golgi are blocked, H-Ras can still traffic to the plasma 
membrane whereas YFP-GT46 is completely restricted on the endomembranes. These 
results make us proposed an alternative pathway for H-Ras moving to the plasma membrane. 
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Then we further discovered this alternative non-classical pathway for H-Ras traffic is non­
vesicular or at least microtubules independent. The initial exporting site for this non-
classical pathway is on the ER and only on the ER. Once H-Ras moves to other membrane 
structures, it cannot use this pathway anymore. 
In the chapter 3 we moved to the signal transductions of H-Ras on the 
endomembranes. The classical signal transduction platform for H-Ras is plasma membrane 
[2-7]. However, during recent years, new evidence has suggested that the plasma membrane 
may not be the only platform for the Ras proteins localization and signal transduction. 
Endomembranes may be the other important sites for Ras proteins signal transduction [8-12]. 
We discovered two H-Ras mutants that are permanently entrapped on the endomembranes. 
Using these two H-Ras mutants as a model, we compared the differences between plasma 
membrane based and endomembranes based signal transduction of H-Ras. We found 
although localized on the endomembranes, two H-Ras mutants show similar effector binding 
property as wild type on the plasma membrane. However, the signal transduction outcomes 
were quite different among these two mutants and wild type H-Ras. The oncogenic form of 
CDQCE mutant showed almost the same potential as wild type H-Ras in making cells lose 
their contact inhibition ability, whereas very decreased competence in cell proliferation. 
SDQCE showed poor potentials in both sides although it localized very similar to the 
CDQCE mutant on the endomembranes. Another feature of these two H-Ras mutants 
signaling on endomembranes is that they both did poorly in inducing PC 12 cells to generate 
neurites. However, CDQCE again showed subtle different signaling from the SDQCE in 
inducing cells to develop a unique phenotype. From these studies we found that different 
membrane localization can affect the signal transduction outcomes of H-Ras. 
Finally the experiments we did in chapter 4 demonstrated that H-Ras proteins 
although showed same membrane fractions as raft membrane in non-detergent gradient 
131 
fractionation, they can be easily separated from the detergent resistant membranes by very 
low concentration of TritonX-100. The active and inactive forms of H-Ras proteins are 
indistinguishable in their locations of detergent based membrane fractionation. The immuno-
fluoresce images also show that H-Ras WT and H-Ras61L are localized in distinct micro-
domains from the specialized lipid raft domain caveolae. These results suggest both active 
and inactive forms of H-Ras are localized in non-raft micro-domains. 
Lipid Modifications 
Lipid modifications play important roles in H-Ras traffic and localizations. The 
mechanism for H-Ras vesicular transportation pathway is though due to the palmitoylations 
at C-terminal cysteines [1, 13-17]. However we found two H-Ras mutants that are 
palmitoylated or putatively fully lipid modified are trapped on the endomembranes. This 
suggests the real mechanism for H-Ras transportation maybe is not as simple as people 
thought. As described in chapter 3, our results suggest H-Ras can use both classical and non-
classical pathways for its plasma membrane targeting. However, the mechanism for this 
traffic divergence is unknown. Maybe the level of lipid modification is the signal. Studies 
from SDQCE and CDQCE mutants also showed that the difference in lipid modification 
could cause a subtle difference in the membrane localizations, and thus induce quite distinct 
outcomes of signal transduction. 
Biological Significance 
Many human tumors are found containing Ras protein mutations and several cancer 
therapies currently in clinical trials are designed to inhibit membrane binding of Ras proteins. 
Some drugs targeted at reducing the abundance of H-Ras on the plasma membrane [18]. Our 
findings that H-Ras may use two pathways for its plasma membrane transportation suggests 
that there are more difficulties to be overcome before this therapeutic strategy will be 
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successful. The studies from SDQCE and CDQCE mutants indicate even the same protein, 
when localized on different membranes, would induce distinct signal events and thus change 
the final effect on the cell. 
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Appendix 
Accompany CD-ROM and Operating Instructions 
System requirements for computer disks: IBM PC or 100% compatibles; Macintosh 
G3 or higher; Windows 95 or higher; MacOS 8 or higer; hard disk (200MB minimum); 
Quicktime™ software. The software can be downloaded from 
http://www.apple.com/quicktime/download/mac.html. 
CD-ROM contains the movie in chapter 3 that shows only very few vesicles carrying GFP-
H-Ras move to the plasma membrane. 
